

Optimization of left ventricular pacing site in cardiac resynchronization therapy using combination of personalized computational modeling and machine-learning

Arsenii Dokuchaev¹, Tatiana Chumarnaya^{1,2}, Anastasia Bazhutina^{1,2},
Svyatoslav Khamzin¹, Viktoria Lebedeva³, Tamara Lyubimtseva^{1,3}, Stepan
Zubarev^{1,3}, Dmitry Lebedev^{1,3}, Olga Solovyova^{1,2,*}

¹ *Institute of Immunology and Physiology, Ural Branch of the Russian Academy of Sciences, Ekaterinburg, Russia*

² *Ural Federal University, Ekaterinburg, Russia*

³ *Almazov National Medical Research Centre, Saint Petersburg, Russia*

Correspondence*:

O. Solovyova
o.solovyova@iip.uran.ru

2 ABSTRACT

3 **Background:** Up to 30-50% of selected patients with chronic heart failure do not respond to
4 cardiac resynchronization therapy (CRT). Optimization of pacing lead placement in ventricles
5 remains a challenge.

6 **Objective:** We utilize a machine learning (ML) classifier to predict the position of an optimal left
7 ventricular (LV) pacing site maximizing the probability of CRT response for a certain patient.

8 **Materials and Methods:** Retrospective data from 57 patients with implanted CRT devices were
9 utilized. Positive response to CRT was defined by a 10% improvement in the LV ejection fraction
10 in a year after implantation. For each patient, a personalized model of ventricular activation and
11 ECG was developed based on MRI and CT images. The total ventricular activation time, QRS
12 duration and electrical dyssynchrony indices during intrinsic rhythm and biventricular (BiV) pacing
13 with clinical pacing lead position (ref-LP) were computed and used in combination with clinical
14 data to train the ML algorithm. We built a logistic regression classifier predicting CRT response
15 with a high ROC AUC=0.84 and an average accuracy of 0.77. It generates a ML-score estimating
16 the probability of CRT response. ML-scores were computed from model-driven features for
17 varying LV pacing sites. Then Bayesian optimization was used to interpolate the ML-score over
18 the available LV surface and an optimal LV lead position for BiV pacing that maximizes ML-score
19 (ML-LP) was defined.

20 **Results:** The optimal LV pacing site position increased the average ML-score by 17% in the
21 patient cohort. Moreover, 11 out of 34 (20%) non-responders classified as true negative at ref-LP
22 were re-classified as positive at ML-LP. In a patient group (n=14, 25% of the cohort) with LV pacing
23 lead deployed in close proximity to the optimal position, the ratio of responders to non-responders
24 was three times higher than in the entire cohort.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 **Conclusion:** We have developed a new technique based on simulations and ML to define an
26 optimal position for LV lead for BiV pacing maximizing the ML-score of CRT response on the
27 available LV epicardial surface. This technique demonstrates a high potential for the improvement
28 of CRT outcome with guided lead implantation.

29 **Keywords:** Cardiac Resynchronization Therapy; Optimal design for pacing lead position; Machine learning; Cardiac modeling;
30 Electrophysiology; Hybrid approach; Prediction; Heart Failure

1 INTRODUCTION

31 In addition to being an optimal medical treatment, cardiac resynchronization therapy (CRT) is an effective
32 therapy for patients with chronic heart failure (CHF). According to the current 2021 patient selection
33 guidelines (1), CRT is recommended for selected CHF patients in sinus rhythm with a reduced left
34 ventricular ejection fraction (LV EF) $\leq 35\%$ and a long QRS duration (QRSd) ≥ 130 ms reflecting
35 left bundle branch block (LBBB). CRT delivers biventricular (BiV) pacing to correct electromechanical
36 dyssynchrony in order to increase cardiac output.

37 Despite the well-documented CRT benefits for improving patient outcomes and reducing patient
38 hospitalizations and mortality in the general population of CRT recipients, it still remains ineffective
39 in 30-50% of cases depending on CRT response definition (2).

40 The problem of CHF patient stratification for CRT implantation and optimization of the procedure
41 and device setting up is addressed in a number of clinical trials and simulation studies and still calls
42 for the community attention (3, 4, 5). Pacing lead configuration for CRT was shown to be an essential
43 determinant of patient improvement (4, 6). Recently, quadripole and multipole left ventricle (LV) leads
44 have become available, which allow an operator to test different LV pacing configurations and choose the
45 most appropriate setting (7, 8, 9). In addition to BiV pacing, His-Purkinje conduction system pacing is also
46 considered as an alternative or additional possibility for optimizing pacing effects (10, 11).

47 Generally, there are two steps in CRT optimization that are being discussed. The first concerns the
48 intra-operative guidance of LV lead implantation. In the standard procedure, a LV lead is introduced into
49 the coronary sinus vein at an appropriate position by intra-operative X-ray imaging guidance based on
50 empiric rules developed by practice but essentially dependent on the operator's experience and skills. Much
51 effort has been devoted to improving lead implantation. Several criteria of intra-procedural optimization
52 have been proposed. Overall, clinical trials suggest avoiding the apical and anterior regions for lead
53 positioning (4). In electrically guided implantation, the narrowing of QRS duration (QRSd) is used to
54 predict the best electrical synchronization (12), but this approach has not shown credible evidence. New
55 techniques of Body Surface ECG Mapping for non-invasive assessment of the ventricular activation are
56 also being developed to improve electrical synchronization (13, 14). Novel cardiac imaging approaches
57 demonstrate the benefits of pre-operational myocardial fibrosis and scar area assessment to avoid proximity
58 to this area when implanting the LV lead (15, 16, 17). Frequently, the late activation time (LAT) area is
59 considered as a target for LV lead implantation (18), assuming that pacing from this area provides more
60 effective electrical synchronization.

61 In mechanically guided implantation, the area of late mechanical activation derived from modern
62 echocardiography imaging data was suggested as a target for LV lead placement (19). However, although
63 a recent systematic study and a meta analysis of the randomized clinical studies using this approach
64 confirmed improvements in the NYHA HF class in the patients, no improvements were found in the
65 LV remodeling and ejection fraction (LV EF) (20). Recent studies using intra-operative evaluation of

66 hemodynamic features showed that an LV lead location maximizing both LV dP/dt_{max} and stroke work
67 has potential for CRT response (21, 3, 8) improvement. Although great efforts have been made to improve
68 LV lead implantation, none of the above approaches is included in the current guidelines for the procedure.

69 The other, more feasible step of LV pacing optimization is post-procedural choice of active pacing sites
70 among the two, four or multiple sites that are available depending on the LV lead configuration (22, 12, 23).
71 Many clinicians consider QRSd shortening or a QRS area reduction as a criterion for pacing pole selection
72 or used echocardiography to control LV EF improvement during device programming. In today's practice,
73 CRT devices are conventionally programmed to pace from the LV active pole with the longest electrical
74 delay (QLV delay). This parameter is measured in the sinus rhythm as the time interval from the ECG
75 Q wave onset to the moment when the electrical wave arrives at the pole of the LV sensing lead (24).
76 Two ongoing trials are also investigating whether a QLV targeted approach is beneficial compared to
77 standard LV lead implantation (DANISH-CRT NCT03280862, ENHANCE CRT NCT01983293). In some
78 studies, interventricular delay (RV-LV delay), as measured by the difference in activation time between
79 the right ventricular (RV) and LV leads in sinus rhythm or at RV pacing is also used to optimize LV lead
80 placement (25, 26). Nevertheless, although the results of numerous clinical trials have demonstrated various
81 potential ways of lead placement optimization, no image-based approach has yet been recommended to
82 guide the implantation strategy in routine practice. This emphasizes the need for further validation of useful
83 imaging-based approaches and the development of new CRT optimization strategies.

84 Although it is generally accepted that the problem of CRT procedure optimization is essentially
85 multifactorial, most of the approaches used to optimize ventricular lead placement have been based
86 on some single features characterizing the resynchronization of the ventricular activation or contraction.

87 Modern machine learning approaches open up new perspectives on the analysis of a variety of patient-
88 specific data that can be obtained using current cardiac imaging techniques of different modality. Recently,
89 the use of unsupervised ML analysis enabled researchers to elicit four phenotypes in a patient population
90 showing different probabilities of improvement due to CRT (27). Using supervised ML algorithms, a ML
91 calculator based on a minimal set of conventional preoperative clinical data was developed to predict LV
92 EF improvement with a high accuracy of about 0.7, which was higher than what other classifiers were able
93 to attain (28).

94 Predictive models have been developed to estimate mortality or hospitalization risks from baseline
95 clinical parameters (29, 30, 31), to assess improvements in LV EF based on baseline indices and analysis
96 of medical records (32), and to stratify patients by an unsupervised learning approach implementing
97 electrocardiography data (27, 33).

98 In current modeling studies, detailed cardiac anatomical models are also used to identify significant
99 features related to CRT improvement (34, 35). In a recent article by Rodero et al. (36), an optimal pacing
100 design with quadripolar LV lead in terms of minimizing total ventricular activation time (TAT) as a measure
101 of the electrical dyssynchrony in ventricles was analyzed using personalized electrical ventricular models.
102 The authors compared the effects of single and multi-site pacing with personalized and population-based
103 optimal lead designs in case of infarct absence. Finally, they concluded that a single optimal lead design is
104 sufficient to obtain near-optimal results across most patients. Moreover, modeling predicts a decreased
105 effect of pacing on TAT reduction due to postprocedural ventricular reverse remodeling, indicating the
106 need to re-tailor optimal lead design in postoperative follow-up. The above study shows the potential of
107 virtual clinical trials as a tool for exploring new pacing lead placement designs.

108 In another recent study, Lee and co-authors (37) showed that simulations from personalized computational
109 cardiac models and image based measured mechanical indices are predictive of an optimal LV lead
110 placement for a positive acute hemodynamic response (37). Using machine-learning (ML) techniques,
111 these authors showed that the combination of the RV-LV electrical delay and mechanical regional time to
112 peak contraction can predict a positive response with an accuracy of about 70%.

113 In our recent proof-of-concept study, we utilized a combination of retrospective clinical data in patients
114 who had undergone CRT, personalized cardiac modeling and an ML approach in order to develop a new
115 technique for predicting the response of conventional BiV pacing prior to the CRT procedure (38).

116 We developed the ML classifier for CRT response based on a hybrid combination of clinical and model-
117 derived data on ventricular geometry and electrical activation at both intrinsic LBBB pattern and BiV
118 pacing (see Fig. 1 for a pipeline of ML-classifier development based on the hybrid data). A total of 7
119 selected model-driven features of myocardial activation and clinical biomarkers are fed to the ML classifier
120 for calculating a ML score which allows one to estimate the probability of a more than 10% LV EF
121 improvement and thus to predict potential CRT responders or non-responders. The ML classifiers on the
122 hybrid dataset outperformed classifiers built upon the clinical data, showing a higher accuracy over 0.8
123 with sensitivity and specificity higher than 0.7. Moreover, the ML score showed a positive correlation with
124 the percentage of LV EF improvement in our patient cohort, suggesting the possibility of a quantitative
125 prediction of the CRT outcome.

126 As a hypothesis for the current work, we suggested that such ML classifier on hybrid data could be used
127 to predict an optimal LV lead position for guiding lead implantation. The idea of the strategy is as follows
128 (Fig. 2). A personalized ventricular model for a given CRT candidate is constructed using imaging data
129 and is then used to calculate ML scores for various LV pacing sites located on the epicardial surface of
130 different LV segments with the exception of carefully defined scarring regions. Then Gaussian process
131 regression is applied to the ML score array for predicting the location of a pacing site at the LV surface that
132 would maximize the ML score of CRT response for the patient. This location can be then used to target LV
133 lead implantation.

134 The effects of ML-based optimal LV lead position on ventricular activation outlined in this study are
135 compared with other strategies for lead placement based on the LAT area and TAT minimization.

2 METHODS

136 2.1 ML classifier of CRT response

137 In the present study, we used the same pipeline to develop a supervised classifier of CRT response as
138 previously described (38) (Fig. 1). The ML classifier was trained and tested on a hybrid dataset consisting
139 of clinical data from patients who had undergone CRT and simulated data from personalized computational
140 models of cardiac electrophysiology.

141 2.1.1 Clinical data

142 The study involved the clinical data from 57 CHF patients. All patients were on optimal drug treatment
143 following CRT device implantation at Almazov National Medical Research Centre between August 2016
144 and August 2019. The participants signed approved informed consent forms. The study protocol was
145 approved by the Institutional Ethical Committee.

146 The criteria for patient inclusion in the study and the complete list of clinical data used to perform
147 feature importance analysis for machine learning classifier development are presented in the Supplementary
148 Materials (sec. Clinical data description).

149 Patients were evaluated before CRT device implantation and during the follow-up period of 12 months
150 after implantation. The baseline clinical data of the patient cohort are presented in Table S1.

151 In addition to the standard protocol of patient evaluation for CRT implantation, we also acquired data
152 from 12-lead ECG and echocardiography recordings prior and after device implantation. Moreover, we
153 collected multichannel ECG with a special system (Amycard, EP Solutions SA). This tool helped to record
154 a maximum of 224 unipolar ECG signals at various pacing configurations (intrinsic rhythm, RV or LV
155 pacing, BiV pacing) during the follow-up in a year after CRT implantation. After recording multichannel
156 ECG, we performed computer tomography (CT) to visualize the torso with applied electrodes and the heart.
157 The series captured with a scanner (Somatom Definition 128, Siemens Healthcare, Germany) were imported
158 into special Wave program version 2.14 (Amycard, EP Solutions SA) to reconstruct the 3-dimensional
159 geometry of the torso and heart. Finally, epi/endo ventricle models were manually built with marked active
160 poles of RV and LV leads deployed for BiV pacing simulations. Data from magnetic resonance imaging
161 (MAGNETOM Trio A Tim 3 T, Siemens AG or INGENIA 1.5 T, Philips) with contrast (Gadovist or
162 Magnevist) before CRT implantation were also used to detect scar/fibrosis area in the myocardium and to
163 incorporate these data into a personalized ventricular myocardial model.

164 **Responders and non-responders.** Patient data were annotated into responder and non-responder groups
165 according to LV EF improvement by more than 10%. Table S2 shows clinical data in the groups, indicating
166 significant differences in the echocardiography indices.

167 2.1.2 Simulated data

168 **Ventricular anatomy models.** Based on the segmentation of CT imaging data, finite element models
169 were constructed for the torso, lungs and RV-LV ventricles for each of the 57 patients (Fig. 1 I. 1.) . A
170 rule-based approach was used to simulate myocardial fibers architecture (39). MRI data on scarring and
171 fibrosis areas in the myocardium were accounted for in the LV model using expert annotation of these areas
172 within the 17-segment American Heart Association (AHA) model of LV (see (38) for more detail). The
173 scar regions were simulated as non-conducting and non-excitable areas and the conductivity of fibrosis
174 regions was decreased by 50%.

175 **Myocardial electrical activation models.** As in the previous work (38), we used an Eikonal model (40)
176 to calculate electrical activation times at each point on the ventricular mesh. Cardiac tissue was simulated
177 as an anisotropic medium with conductivities resulting in an excitation velocity ratio of 4:1 along vs across
178 the myocardial fibers. The Eikonal model is currently widely used; it allows one to simulate the evolution
179 of the cardiac excitation wavefront (41, 42, 43, 44, 45).

180 ECG calculation was performed using the Lead Field method proposed by Pezzuto et al. (42, 46). ECG
181 signals were computed according to the standard 12-lead ECG definition and the lead-field approach
182 allowed us to reduce calculation time more than 100x times.

183 **Model parameter personification.** Each patient-specific model assumed a uniform conductivity in the
184 myocardial tissue across the entire ventricles. Then an optimization problem was solved for each of these
185 models to estimate the global conductivity parameter, and minimize discrepancy between simulated and
186 clinically measured QRS complex durations from 12-lead ECGs recorded in the patient. We used the
187 L-BFGS-B algorithm to handle optimization in the model and the method proposed in (47) for automatic
188 QRS onset and offset detection.

189 **Pacing protocols.** We simulated two pacing protocols – LBBB activation pattern and BiV pacing, and
190 calculated model-derived features to be used for developing an ML classifier of CRT response.

191 To simulate the LBBB activation pattern, the RV endocardial surface was annotated and a Purkinje
192 network was generated using the model proposed by Costabal et al. (48). The Purkinje system was isolated
193 from the working myocardium and connected to it only at the ends of the Purkinje fibers. Activation started
194 at the His node and spread throughout the conduction system with an excitation velocity of 3 mm/ms
195 before approaching Purkinje-myocardial junction points. This activation map was then applied to initiate
196 activation within the ventricular myocardium according to the Eikonal model.

197 Furthermore, we used the simulated LBBB ventricular activation map to define the area of LAT in every
198 patient model. This area was then used as one of the optimal LV pacing site positions, and the effects of
199 this pacing optimization were compared against other designs (see next section below).

200 For BiV pacing we used referent RV and LV pacing lead locations derived from CT images. A zero time
201 delay was set between the RV and LV pacing sites as programmed in patients.

202 For both the LBBB and BiV protocols, the global conductivity parameters were fitted to the 12-lead ECG
203 data recorded from the patients.

204 **Simulated features used for developing ML-classifiers.** Patient-specific models allowed us to identify
205 several clinically important features affecting ventricular activation and the geometric properties of
206 ventricles.

207 The first group of model-derived indices was defined from the ventricular anatomy models based on
208 CT and MRI data, coupled with electrophysiological model simulations. We estimated the volume of
209 postinfarction scar and non-ischemic fibrosis and their size relative to the myocardial tissue volume (MTV).
210 Knowing the exact location of RV and LV pacing leads, we measured the time delay in the activation of the
211 LV electrode later than the RV electrode (RV-LV delay) in LBBB. We also calculated the physiological
212 distances between the RV and LV pacing sites (RV-LV distance), and the distances from the LV lead to the
213 scar area (Scar-LV distance) and to the area of LAT (LAT-LV distance) under intrinsic rhythm, by solving
214 an isotropic Eikonal equation, to define the distance from a certain point on the ventricular surface to a
215 specific area. The latter distances mimic ones that can be directly measured from CT and MRI images by a
216 ruler.

217 The second group of model-derived indices were calculated for LBBB and the BiV pattern of myocardial
218 activation. We simulated activation maps and 12-lead ECG signals. Final calculations included the following
219 biomarkers for both pacing modes: total ventricular 95% activation time (TAT95), computed as the time
220 interval for 95% ventricular activation; maximum QRS complex duration; time delay between the total
221 LV and RV activation time (AT_{RV-LV}); relative difference between the mean activation time of the LV
222 free wall and septum ($mAT_{STLV} = (LVlat_{mean} - ST_{mean})/TAT$, where $LVlat_{mean}$ (ms) is the average
223 activation time of the LV free wall, ST_{mean} is the average activation time of the septum, and TAT is the
224 total ventricular activation time. Changes in indices at BiV pacing compared to LBBB in either absolute
225 values or normalized to the LBBB values were also used for developing the ML classifier of CRT response.

226 A summary of simulated data is presented in Tables S1, S2 in Supplementary materials.

227 2.1.3 Machine learning model

228 We built ML classifiers based on the hybrid dataset containing the clinical and model-derived indices
229 described above. The complete list of the clinical and simulated features fed to ML algorithms is shown in
230 Figure S3. To train ML classifiers, the dataset was labeled as responders and non-responders according to the
231 definition of response to CRT as an increase of more than 10% in LV EF. (38).

232 At the preprocessing step, non-categorical data were normalized by subtracting the mean and dividing
233 by standard deviation. Highly correlated features were also removed from the dataset by threshold > 0.85 .
234 The next step was to select a set of most significant features for CRT response prediction. Feature selection
235 was done using a Leave-One-Out cross-validation technique: for each patient, we formed a training dataset
236 from which we excluded that patient's features and then predicted the ML Score value for that patient.

237 The logistic regression (LR) classification algorithm was trained on the hybrid dataset, and 7 most
238 significant features with the highest LR weights were chosen as follows: 3 pre-operational clinical features:
239 left ventricle ejection fraction before CRT (LV EF, %), body mass index (BMI, dimensionless), and end-
240 diastolic diameter of LV (EDD, mm). Also, 4 model-derived features were taken into account: distance from
241 LV pacing site to postinfarction scar area (Scar-LV distance, mm), total activation time 95% myocardium
242 in the LBBB activation pattern (TAT95, ms), and inter-ventricular dyssynchrony indices in LBBB and at
243 BiV pacing ($AT_{RVLV,LBBB}$, $AT_{RVLV,BiV}$, ms).

244 Finally, these 7 features were used to train the final LR classification model. The features and
245 corresponding logistic regression weights are listed in **Supplementary Table S3**. The LR classifier
246 generates an ML-score based on the clinical and simulated features of the patient, which gives an estimate
247 of the probability that the patient would respond positively to CRT. These ML-scores then were combined
248 into one set to build a receiver operation characteristic (ROC) curve, and the area under the ROC curve
249 (AUC) was calculated (Fig. S1 in Supplementary Materials). A threshold value of the ML-score=0.5 was
250 adopted to predict either positive (ML-score ≥ 0.5) or negative (ML-score < 0.5) response to CRT in our
251 patient cohort.

252 **2.2 Optimization of LV pacing site position based on the ML-score**

253 In step of the study, we used the final LR classifier to predict an optimal LV pacing lead position which
254 maximizes the ML-score throughout the LV epicardial surface for each personalized model of the cohort
255 (see Fig. 2 for the pipeline employed for searching an optimal LV lead position). Septal regions and scarring
256 area were excluded from possible LV pacing site locations. First, we varied the position of the LV pacing
257 site between the centers of LV AHA segments on the epicardial surface with the RV pacing site located at
258 the clinical position derived from the CT scan.

259 For each LV lead position (up to 12 positions, 10 per model on average), we computed the
260 electrophysiological model and extracted model-derived features from the simulations and fed them
261 into the LR classifier to generate the ML-score. At the end of this step, an initial distribution map of the
262 ML-score on the LV epicardial surface was generated. The small number of points with defined ML-scores
263 did not allow us to accurately predict the optimal LV pacing site with maximum ML-score. Therefore, we
264 used a Bayesian optimization method to interpolate the ML-score on the entire LV surface accessible for
265 pacing. This method involves building a regression model and its iterative refinement before converging at
266 the optimal solution.

267 **Bayesian Optimization.** Bayesian optimization is a derivative-free global optimization method that
268 requires only a model evaluation function.

269 The iterative process of ML-score interpolation was performed using Gaussian process regression (GP
270 regression) model (49). We used the current ML-score set (an initial pre-calculated ML-score vector in the
271 first iteration step) to train GP regression and to predict the ML-score at every point on the LV epicardial
272 surface (at every node of the mesh). Then we calculated the so called acquisition function: $L(\mu, \sigma) = \mu + 2\sigma$,
273 where μ is an expected ML-score value predicted by GP regression and σ is a standard deviation of GP at
274 this point (GP uncertainty value) (Fig. 2, step 2). After that, maximum $L(\mu, \sigma)$ was defined throughout the

275 LV nodes, and this position was further used to calculate the electrophysiological model at BiV pacing
276 with this LV pacing site and to compute the corresponding ML-score according to the LR classifier fed
277 with new simulated features.

278 The Bayesian optimization method thus strikes a balance between finding points that allow one to refine
279 the GP regression model (points with large uncertainty, i.e., large σ), and finding points where the value of
280 the regression function is maximum (points with maximum μ).

281 In the next iteration step, GP regression was re-trained with the addition of the data from the new point on
282 the LV surface and the algorithm was repeated. The optimal solution was considered to be found if the last
283 two iterations of the Bayesian optimization algorithm predicted the same point. Finally, we obtained an LV
284 epicardial surface map of ML-score values, predicting areas of LV pacing with either positive (ML-score
285 ≥ 0.5) or negative (ML-score < 0.5) expectation of response to CRT and suggested the optimal position of
286 LV pacing site maximizing the ML-score among all available LV surface positions. This map can guide LV
287 lead placement during CRT implantation.

288 **2.3 Optimization of LV pacing site based on LAT area or TAT reduction**

290 In addition to the ML-score based optimization of pacing lead position in the personalized models, we
291 also used LAT area defined in LBBB for LV pacing site location, as suggested in several clinical studies
292 (50, 51). Another approach to LV pacing site optimization in our models was based on the minimization
293 of TAT95, which is also considered as a target for LV lead positioning (52). The latter approach was
294 implemented in our personalized models using an iterative procedure similar to the one we used for
295 ML-score optimization. To this end, we generated an initial set of simulated TAT95 with BiV pacing
296 under variation in the LV pacing site position between ventricular segments and further used Bayesian
297 optimization of TAT95 over the available LV surface. As a result, we found an LV pacing site position with
298 minimal TAT95 on the available LV surface in each personalized model of our cohort.

299 The effects of each of the approaches to LV pacing site optimization were compared with the effects at
300 the clinical LV lead position and with each other.

301 **2.4 Software**

302 Cardiac electrophysiology was simulated using an in-house software based on the FENICS library (for
303 solving PDE problems) (53) and VTK (for working with meshes). The scikit-learn library was employed
304 for the machine learning: classifier development, statistical modelling, feature selection, cross validation,
305 and ROC-AUC calculation, and the Pyro (54) library for GP regression and Bayesian optimization.

306 **2.5 Statistics**

308 Detailed analysis was performed using the IBM SPSS Statistics 23.0.0.0 software package (USA). For
309 qualitative data, the frequency and percentage of total patients in the cohort were calculated. Quantitative
310 data are presented as mean \pm standard deviation. Comparisons between two dependent groups were made
311 using Wilcoxon's test for quantitative data and McNemar's test for qualitative data. Comparisons between
312 dependent groups (ref-LP and opt-LPs vs LBBB; opt-LPs vs ref-LP) were made using nonparametric
313 Friedman's two-way ANOVA, followed by a pairwise comparison adjusted for multiple comparisons.
314 Comparison between two independent groups (non-responders vs responders) was carried out using Mann-
315 Whitney test for quantitative data and Pearson's chi-square test for qualitative data. Feature dependence
316 was assessed using Spearman rank correlation test. The critical level of statistical significance was taken

317 equal to 0.05.

318

3 RESULTS

319 **3.1 Hybrid dataset of clinical data before and after CRT device implantation and model** 320 **simulations in LBBB and at BiV pacing**

321 Retrospective clinical and imaging data from 57 patients who had undergone CRT implantation were
322 collected and analyzed. Each patient-specific RV and LV pacing lead positions as deployed during the
323 implantation procedure were derived from the CT-scan and used further as a reference pacing lead position
324 (ref-LP). RV electrodes were placed at a standard apical position in all the patients. Figure S2 shows the
325 distribution of the referent LV pacing sites between the segments according to the 17 segment AHA LV
326 model. It can be seen that in 50 (88 %) out of the 57 cases the LV lead was placed in the lateral wall, mostly
327 in the mid- and basal segments. The LV lead was delivered to the inferior segment in only one case and to
328 the anterior segments in 5 cases. In 2 participants, an apical LV lead position was observed.

329 The location and transmuralty of myocardial postinfarction scar and fibrosis were defined from MRI
330 image description (see Methods for detail). Figure S2 shows the distribution of the segments with scar and
331 fibrosis between the 17 AHA LV segments in the patient cohort. In 10 (18%) out of the 57 patients the
332 segments with implanted LV electrodes were concordant.

333 A population of personalized ventricular electrophysiology models was built for the patient cohort. The
334 ref-LP was used to evaluate the effects of BiV pacing in the personalized models. A summary of the
335 statistics for clinical data, CT/MRI derived data and model-driven biomarkers in the patient cohort is
336 presented in Supplementary Materials S1.

337 The entire patient cohort showed an average positive response to BiV pacing, revealing itself in a
338 decrease of $-23\pm 14\%$ in QRSd, a reduction in the end-diastolic and end-systolic volume (EDV and ESD,
339 correspondingly) by -18 ± 31 and $-24\pm 36\%$, and in LV EF improvement by $9\pm 8\%$ as compared with
340 pre-implantation data. In consistency with the clinical data, average positive changes in the simulated
341 features of myocardial activation in response to BiV pacing manifested themselves as a decrease in
342 QRSd by $-23\pm 13\%$, in TAT95 by $-32\pm 17\%$, and in all computed indices of the inter- and intraventricular
343 dyssynchrony by about 100% **see Table 1**.

344 The hybrid dataset combining clinical and model-driven data in our patient cohort was then classified into
345 responders ($n=23/40\%$) and non-responders ($n=34/60\%$) to CRT according to the LV EF improvement of
346 more or less than 10% (referred to below as the EF10 criterion). The two groups demonstrated significant
347 distinctions in several indices associated with CRT response. Table S2 in Supplementary Materials compares
348 the clinical and model-derived variables of the groups.

349 According to the classification criteria, the average LV EF improvement by $17\pm 5\%$ in the responders
350 group is well above $3\pm 5\%$ for non-responders. The average reduction in EDV and ESV is about 5 times
351 larger in responders. At the same time, in consistency with the clinical data, no difference in the relative
352 decrease in both simulated TAT and QRSd at BiV pacing was found between the two sub-populations of
353 models.

354 Regarding the CT/MRI derived geometry indices, we found that in 2 (9%) responders and in 8 (24%)
355 non-responders the segments with implanted LV electrodes were concordant with scar area. Accordingly,
356 a shorter distance from the LV pacing site to the scar/fibrosis zone in the non-responders group (26 ± 24
357 mm in non-responders vs 39 ± 22 mm in responders) was revealed, suggesting less effective pacing of the

358 normal tissue in non-responders. No other indices showed any significant difference between the groups
359 (see Table S2 in Supplementary Materials).

360 **3.2 ML-classifier of CRT response built on a hybrid dataset**

361 As we showed in our previous study (38), none of the individual biomarkers in the intrinsic LBBB
362 activation pattern derived from either clinical or CT/MRI data allowed us to classify the responders and
363 non-responders groups with a sufficient accuracy. Similarly, none of the simulated electrophysiological
364 biomarkers enabled us to distinguish between the groups both in the LBBB mode of activation and at
365 BiV pacing (see Table S2 in Supplementary Materials) and, thus, consider them as individual classifying
366 features.

367 This prompted us to use a combination of the clinical data recorded prior to the operation and MRI/CT
368 derived biomarkers together with simulated features from personalized models of ventricular excitation
369 in the LBBB and BiV pacing activation modes to build an ML-classifier, which improved significantly
370 the accuracy of CRT response predictions in our patient cohort. The features fed into the feature selection
371 algorithms when developing CRT response classifiers are listed in Figure S3 in the Supplementary Materials
372 in the descending order of feature importance.

373 We used the hybrid dataset containing 57 data entries for every patient from our cohort. The supervised
374 classifiers were trained using an EF10 criterion ($\Delta EF > 10\%$) of CRT response. In this article, we developed
375 a Logistic Regression (LR) classifier using Leave-One-Out and five-fold cross-validation and 3 different
376 feature selection methods inside the cross-validation loop to train the classifier. Seven most important
377 features were selected for developing the final LR classifier used further below in this article (see Table S3
378 for the LR independent variables and coefficients). The feature sub-set contains 3 pre-operational clinical
379 features: LV EF, %, body mass index (BMI, dimensionless), end-diastolic LV diameter (EDD, mm); and 4
380 model-driven features: distance from LV pacing site to scar area (Scar-LV distance, mm), total activation
381 time of 95% of myocardium in the LBBB activation pattern ($TAT_{95_{LBBB}}$, ms), and inter-ventricular
382 dyssynchrony indices in LBBB and at BiV pacing ($AT_{RVLV,LBBB}$, $AT_{RVLV,BiV}$, ms).

383 The best supervised LR classifier we developed features a high ROC AUC of 0.84 with a total accuracy of
384 77%, sensitivity of 65% and specificity of 85% (see the complete list of the classifier characteristics in Table
385 S3 in Supplementary Materials). Based on the hybrid clinical and model data, the LR classifier calculates an
386 ML-score of CRT response as an estimate of the probability of a higher than 10% LV EF improvement for
387 a patient. The threshold ML-score classifying patient data into the responders or non-responders group was
388 found to be 0.5. This value will be used hereafter to classify test data in various LV pacing configurations.

389 The ML-score generated by the LR classifier allowed us to distinguish between the groups (0.64 ± 0.30 vs
390 0.25 ± 0.22 , $p < 0.01$, see Table S2). Moreover, the ML-score correlates with post-operative improvement in
391 the EF ($r = 0.57$, $p < 0.001$).

392 These findings convinced us to use the ML-score from the LR classifier to evaluate the effects of
393 pacing lead position on CRT response prediction and to suggest an ML-based strategy for lead placement
394 optimization.

395 **3.3 Optimal pacing lead position based on the model simulations and ML prediction of CRT 396 response**

397 In the previous section, we trained our LR classifier using post-operative CT data on precise clinical
398 location of RV and LV lead pacing sites. However, when we use the classifier to compute an ML-score for
399 selecting CRT candidate prior to the procedure, we do not know the exact lead location. In this section, we

400 describe a technique that uses ML classifier to define an optimal LV lead position (opt-LP) maximizing the
401 ML-score of CRT response for a given patient.

402 A general scheme of the technique for pacing site optimization based on ML-score is shown in Figure
403 2. A personalized ventricular model for a given CRT candidate is constructed using imaging data and
404 employed to calculate model-driven features in the LBBB activation pattern and at BiV pacing with various
405 LV pacing sites located on the epicardial surface in the centers of LV segments. Septal segments are
406 excluded from LV stimulation area tested as unavailable for the transvenous approach. Neither are scarring
407 regions used for stimulation as non-excitable. The selected clinical data and model-driven features for
408 every tested pacing configuration are then fed into the LR classifier we developed to compute ML-scores.
409 At the next step, Gaussian regression is applied to the ML-score array on the LV surface for predicting
410 the location of the pacing site that maximizes the ML-score of CRT response for the patient. If the best
411 possible ML-score corresponding to the opt-LP is higher than the threshold value of 0.5, this patient is
412 classified as a responder. In this case, the opt-LP could be used to guide targeted LV lead implantation.

413 Hereinafter in the text, we refer to the BiV pacing configuration using the CT-derived spots of RV
414 and LV lead tips as the reference lead positions (ref-LP) for each patient-specific model. The simulated
415 characteristics of ventricular electrical activity for different opt-LP criteria are compared with model results
416 for the original LBBB activation pattern, BiV pacing from ref-LP, and between each other.

417 3.3.1 ML-score based optimal LV pacing site *versus* reference lead position

418 Figure 3 shows three examples of optimal LV pacing sites in personalized ventricular models. Two-color
419 maps of the ML-score value are shown on the LV epicardial surface of the personalized models and on
420 the LV AHA segment schemes. Red shades show ML-scores >0.5 (see the color scale in the Figure) in
421 desirable LV segments with pacing sites predicting a positive response to CRT. In contrast, shades of blue
422 show ML-scores <0.5 in LV segments unwanted for LV pacing. Blue and red dots on the map show the
423 locations of the clinical and optimal LV pacing sites, respectively.

424 The left panel in Figure 3 demonstrates the ML-score map in a clinical responder (patient #2) with LV
425 EF improvement of 12%, which is higher than 10%. Here, the referent and optimal pacing sites are located
426 in adjacent LV segments and the maximum ML-score of 0.95 at ML-LP is slightly above the referent value
427 of 0.94. So, this patient is predicted as a true positive for CRT response (ML-score >0.5) at both the ref-LP
428 and ML-LP. It is interesting that the patient is predicted as positive to CRT with any available LV site
429 located at the lateral wall. The LR prediction is in line with the great extent of LV EF improvement in this
430 patient.

431 The center panel in Figure 3 shows the ML-score map for a clinical non-responder (patient #1). Here,
432 the ML-scores at both the referent and optimal LV pacing sites are blue colored (0.14 and 0.27 < 0.5 ,
433 respectively). Moreover, the overall map of ML-scores on the entire available LV surface is blue colored,
434 predicting a low possible response to CRT in this patient. Correspondingly, this patient has a large
435 postinfarction scar spreading over half of the LV segments, and LV EF improvement in this patient is 7% ,
436 which is less than 10%.

437 The right panel in Figure 3 shows the ML-score map for a clinical non-responder (patient #7). The
438 patient with an LV EF of 6% was classified by the LR predictive model as a true negative at the clinical LV
439 pacing lead location (ML-score=0.38, see the referent pacing lead located in the blue color area on the
440 ML-score map). At the same time, our algorithm predicts a narrow red area at the basal inferior segments
441 where the patient is predicted as a positive for CRT response, particularly with the optimal ML-based LV
442 lead position (ML-score=0.77, see optimal pacing site located in the red color area on the ML-score map).

443 Thus, our simulations suggest that this patient could possibly improve with the ML based optimal pacing
444 lead placement (ML-LP).

445 Figure 4 compares the distributions of the ML-scores for the reference and optimized LV pacing sites.
446 The average ML-score for the ML-score based opt-LP (ML-LP) is higher as compared to that for ref-LP
447 (0.58 ± 0.30 vs 0.41 ± 0.31 , $p < 0.01$). In particular, the ML-score is increased in 88% of the patients (51
448 out of 57, 19 responders and 32 non-responders). Importantly, our model predicts a much higher increase
449 (almost double) in ML-score for ML-LP in the non-responders group (see Table 2).

450 In a majority of models (52 (91%) out of the 57 models), BiV pacing from ML-LP reduces considerably
451 all simulated features characterizing ventricular activation as compared with the LBBB models. The average
452 TAT (104 ± 26 ms) and QRSd (146 ± 27 ms) at ML-LP are significantly shorter ($p < 0.01$) than those at
453 LBBB activation (150 ± 26 and 189 ± 24 , respectively). At the same time, no significant difference in
454 average TAT and QRSd was found between ML-LP and ref-LP (Table 1).

455 Both the inter- and intra-ventricular dyssynchrony indices in the LBBB activation pattern have positive
456 average values reflecting significantly later activation of LV *versus* RV, and LV lateral wall *versus* septum
457 (Table S5). Both indices reduce several times at ML-LP as compared with LBBB. However, no difference
458 between ML-LP and ref-LP was found in the inter-ventricular dyssynchrony index AT_{RVLV} , showing
459 a delay in total activation between LV and RV. In contrast, the intra-ventricular dyssynchrony index
460 mAT_{STLV} , representing the difference in total activation time between the lateral LV wall and septal part
461 of LV, is slightly higher for ML-LP. The average positive mAT_{STLV} (0.09 ± 0.06) at ML-LP suggests later
462 activation of the LV lateral wall as compared to the septum, while the negative index (-0.07 ± 0.10) at
463 ref-LP reflects later activation of the septum.

464 3.3.2 Optimal ML-score based LV lead position *versus* other optimized LV lead placement

465 In this subsection, we compare the ML-LP results with other opt-LPs based on different criteria used to
466 optimize lead placement in clinical studies.

467 First, we defined the latest electrical activation time (LAT) area on the LV subepicardial surface in the
468 LBBB activation pattern. Then, we used these LAT spots for LV pacing (referred to hereafter as LAT lead
469 position, LAT-LP) in patient-specific models, calculated the ventricular electrical activation features and
470 fed them together with clinical data into the LR classifier to predict ML-scores of CRT response under
471 LAT-LP pacing for the patients.

472 In addition, we defined a model feature based opt-LP minimizing a certain single model-derived feature
473 characterizing ventricular activation. We tested opt-LP based on either minimal QRSd or TAT, or LV
474 electrical dyssynchrony indices derived from model simulations. Here, we again used a similar Gaussian
475 regression approach for predicting the optimal feature value on the LV surface as employed for ML-score
476 optimization. Note that the same reference RV pacing site was used for each of the tested opt-LP, unless
477 otherwise specified. We then compared the effects of optimized LV pacing positions between ML-LP,
478 LAT-LP and minimum TAT based opt-LP (TAT-LP).

479 A summary of the model-derived features characterizing ventricular activation and ML-scores generated
480 by LR classifier of CRT response using model-derived features of different opt-LP is presented in Tables 1,
481 2, S5 and S6. First of all, we compared ML-scores predicting the probability of LV EF improvement with
482 different pacing lead configurations based on the model simulations.

483 Figure 4 compares the distributions of ML-scores generated by the LR classifier of CRT response
484 using the features simulated for different opt-LPs at BiV pacing. The only maximum ML-score based

485 optimization of LV pacing site predicted an increase in the average ML-score in our patient group as
486 compared with ref-LP and other tested lead configurations (Table 2). Unexpectedly, no difference in the
487 average ML-score was found between optimized LAT-LP, TAT-LP and ref-LP in the entire population. Each
488 optimized LV lead position predicted a higher ML-score in the responders group versus non-responders.
489 However, only ML-LP pacing caused an increase in ML-scores in each group, showing a much higher
490 increase in the non-responder group (Table 2).

491 As defined above, the ML-score=0.5 is a threshold separating potential responders and non-responders
492 according to our LR classifier trained on the ref-LP data. For each opt-LP, we found cases where our LR
493 predictive model classified a patient into the opposite group as compared to ref-LP. In other words, we
494 found patients who were classified as negative (potential non-responders) with ref-LP but re-classified as
495 positive (potential responders) with opt-LP and vice versa. Figure 5 shows such transitions from the group
496 of ML-score<0.5 to the group of ML-score>0.5 and back due to opt-LP pacing in the model. It can be seen
497 that in the case of ML-LP pacing (left panel), there are only upwards transitions from the underside group
498 of potential non-responders with an ML-score <0.5 for ref-LP to upside group of potential responders with
499 an ML-score >0.5. There are 11 such transitions, which are shown in Table S7 in more detail. Here, 5
500 responders classified by the LR classifier as false negative in ref-LP move upward into the positive group in
501 ML-LP (see +5 in the top left cell coming up from the bottom left cell). Moreover, 6 non-responders truly
502 classified as negative in ref-LP are re-classified as positive in ML-LP (see +6 in the top right cell coming
503 up from the bottom right cell). In total, according to the LR classifier the ratio of positive to negative CRT
504 responses with optimized ML-based pacing lead placement rose considerably to 31-to-26 (54-to-46%)
505 versus 20-to-37 (35-to-65%) in ref-LP.

506 In contrast to ML-LP pacing, LAT-LP and TAT-LP pacing did not show such promising predictions (Fig.
507 5, Table S7). There are far fewer positive transitions from negative to positive predictions (4 for LAT-LP
508 and 3 for TAT-LP) with these opt-LP. Moreover, there is a number of reverse transitions from positive to
509 negative prediction in opt-LP (3 for LAT-LP and 6 for TAT-LP), making one to anticipate an unlikely CRT
510 response as compared to ref-LP. In total, the ratio of positive to negative predictions in our population for
511 LAT-LP and TAT-LP is not improved as compared with that in ref-LP pacing (Table S7).

512 3.3.3 Effects of different opt-LPs pacing on simulated features

513 To explain the difference in the distributions of ML-scores depending on pacing lead configuration, we
514 compared the model-derived features characterizing ventricular activation in different opt-LPs. While BiV
515 pacing at every optimized LV lead position reduces ventricular dyssynchrony as compared to the LBBB
516 activation pattern, only opt-LP minimizing LV TAT causes a significant reduction in the average TAT and
517 QRSd in the entire population as compared to ref-LP, ML-LP, and LAT-LP (Table 1, Fig. 4). No difference
518 in both TAT and QRSd was found between the latter three opt-LPs (Table 1). No correlation between
519 TAT and LV EF improvement ($r=-0.20$, $p=0.134$) was found for ref-LP pacing. So, the shortest TAT could
520 unlikely predict with confidence the best response in the patients.

521 Similarly, there were no effects of pacing configuration on TAT and QRSd in the responders and
522 non-responders groups except for TAT-LP, which shortened these features in each group. No significant
523 difference between the groups was found independently of the BiV pacing configuration.

524 The inter-ventricular dyssynchrony index AT_{RVLV} reduced under BiV pacing by about 100%
525 independently of LV pacing site optimization approach in the entire population, and no difference in
526 change in the index was observed between the responder and non-responder groups (Table S5). Similarly,
527 the intra-ventricular electrical dyssynchrony index mAT_{STLV} significantly reduced under BiV pacing as

528 compared to the LBBB activation pattern, and there was not much difference in the index between the
529 opt-LPs and between responders and non-responders.

530 Thus, the peculiarities of these model features under different opt-LPs could not explain the differences
531 in the ML-score we found.

532 As described above, the distance from the LV pacing site to postinfarction scar area (Scar-LV distance)
533 was selected as one of the significant model-driven features affecting LR classifier accuracy, and ML-score
534 value. The average Scar-LV distance is significantly higher for ML-LP as compared to ref-LP, LAT-LP and
535 TAT-LP, contributing to the higher ML-scores for this stimulation pattern. This conclusion is supported by
536 the correlation ($r=0.673$, $p=0.000$) found between the improvement in the ML-score and the extension of
537 the Scar-LV distance when switching the pacing lead configuration from ref-LP to ML-LP.

538 Comparing the responder and non-responder groups, we observe that the distance from LV lead to scar is
539 shorter for the non-responder group for ref-LP, while in ML-LP the distance is significantly increased in the
540 non-responder group, blurring the difference between the groups (Table 2). This contributes to a stronger
541 improvement of the ML-score in the non-responder group under ML-LP pacing. Finally, no correlation
542 between maximal ML-score and the Scar-LV distance was found for ML-LP. In contrast to ML-LP, the
543 Scar-LV distance reduced for LAT-LP as compared to ref-LP (Table 2). This could have been expected,
544 since the electrical propagation should slow down closer to the scarring areas. Hence, the LAT area could
545 be close to the scar. Unexpectedly, the Scar-LV distance reduced with TAT-LP as well, compared to ref-LP
546 (Table 2).

547 For both LAT-LP and TAT-LP, the reduction in Scar-LV distance is larger in the responders group so that
548 the overall effect of such opt-LP on Scar-LV distance in the entire group is not significant.

4 DISCUSSION

549 4.1 ML-score based optimal LV lead position

550 In this study, we have developed an LR classifier of CRT response predicting a positive long-term LV
551 EF improvement of more than 10%. This classifier is based on pre-operative clinical data in combination
552 with simulated features from personalized ventricular anatomy and electrophysiology model computing
553 ventricular activation in the LBBB pattern and under BiV pacing. The classifier was trained and tested
554 on the data obtained from BiV pacing with reference RV and LV lead locations as that delivered in the
555 clinic. The precise RV/LV pacing lead sites were determined from the post-operative CT scans and used in
556 personalized ventricular models for BiV pacing. This was performed to exclude the effects of uncertainty
557 in lead position on the ML prediction results. The classifier showed a great accuracy of more than 0.8
558 with a sensitivity and specificity over 0.7. This was the first step in the validation of our new technique
559 suggesting its high potential for CRT response prediction.

560 In actual practice, such an ML classifier should be used before the procedure when the lead position
561 is yet uncertain. Moreover, a good prognostic model should help to first decide whether a patient should
562 be selected for CRT and, on top of that, help with procedure planning once the patient has been selected.
563 The main advantage of using personalized computational models is the possibility of computing the
564 characteristics of ventricular activation from any accessible pacing sites and to predict an optimal lead
565 placement against certain optimization criteria prior to the procedure. ML classifier allows one to estimate
566 a probability of CRT response for various opt-LPs and help with decision making.

567 In this article, we propose a novel approach to using a ML classifier directly for choosing LV lead
568 position on the LV surface. The patient assessment algorithm involves building a personalized ventricular

569 model, performing simulations in the LBBB activation mode and at multiple LV pacing site positions for
570 BiV pacing. It then involves calculating the ML-score using the LR classifier based on clinical data and
571 model-derived characteristics for each BiV pacing configuration, and finally, applying Gaussian regression
572 with respect to the ML-score throughout the entire LV surface (Fig. 2). Thus, this approach provides a
573 CRT operator with a surface ML-score map that predicts areas of LV pacing lead location with either
574 positive (ML-score>0.5) or negative (ML-score<0.5) predictions of LV EF improvement. Moreover, this
575 approach suggests a target position for optimal LV lead placement that maximizes the ML-score, predicting
576 the highest possible probability of response to CRT (Fig. 2). If the optimal ML-score is high enough
577 (higher than 0.5 in the case of our LR classifier), the patient could be considered a candidate for CRT. The
578 ML-based optimal LV lead position (ML-LP) could serve as a target for lead implantation (see examples of
579 ML-score maps in patient specific models in Figure 3).

580 Existing lead optimization strategies are predominantly based on a single pre- or intra-operative feature
581 (either e.g. LAT, or QRSd, or TAT, or LAT, or dP/dt_{max} , etc.). In contrast to these strategies, our ML-based
582 lead optimization accounts for several significant features related to the CRT response. This approach
583 includes realistic model-driven data on the size and location of the myocardial damage area, distance
584 between the LV pacing site and the scarring area, and simulated features of ventricular activation at BiV
585 pacing from certain LV pacing sites.

586 In fact, we did know the response to CRT in our patients with just one reference pacing lead configuration
587 (ref-LP). Therefore, we first compared the results of optimal BiV pacing design with those of ref-LP, and
588 the ML-score predicted by our LR classifier was used as an estimate of the probability of CRT response
589 depending on lead configuration.

590 The most essential result of our study is that the maximal ML-score based opt-LP (ML-LP) provides the
591 highest ML-score in our patient population among the pacing configurations we tested (Fig. 4, Table 2).
592 This result was to be expected but was not obvious. Indeed, we were sure that variations in LV pacing site
593 location throughout the available LV surface (with the exception of the septal segments and scarring area)
594 would affect the ML-score essentially. The ML-score varied more than 10-fold across the LV surface, and
595 the range was much broader in the non-responders group of patients. This allowed our algorithm to choose
596 a maximal ML-score value for each patient, which exceeded the reference value by $17\pm 14\%$ in 89% of our
597 patients. Moreover, in the non-responders group the maximal ML-score increased by 19% in 32 out of
598 34 patients. This high potential of ML-based optimization of pacing lead placement is clearly visualized
599 in Fig. 5. It shows a great number of transitions among the patients classified at ref-LP into the group of
600 negative expectation for CRT response (ML-score < 0.5) to the group of positive expectation (ML-score >
601 0.5) at ML-LP. It is especially promising that 6 true non-responders in ref-LP are predicted as positive for
602 CRT response in ML-LP pacing.

603 **4.2 Validation of the optimal ML-LP approach**

604 Working with retrospective clinical data in the present study, we had no possibility to verify our predictions
605 of optimal LV lead position with maximum ML-score in a prospective group of patients. That is why we
606 chose to start working with clinical data having the referent LV pacing lead (ref-LP) deployed during the
607 procedure close to the optimal position of the pacing site (ML-LP) predicted from our simulations. The
608 proximity of the referent pacing site to an optimal position was defined as 25% of the shortest distance
609 from the distribution of the distances in our population of 57 patients (lower quartile).

610 There are 14 models in this suboptimal group (with a suboptimal referent LV lead position). The distance
611 from the referent to the optimal LV pacing site position varies from 0 to 26 mm. In 8 models the optimal

612 and referent LV sites are located in the same LV segment of the 17-segment AHA model, while in the
613 other 6 models, - in neighboring segments. There are 9 responders and 5 non-responders in the suboptimal
614 group. Our ML-classifier predicts 11 positive responses with an ML-score >0.5 for ML-LP and 3 negative
615 responses with an ML-score <0.5 . From the 11 individuals predicted as positive in ML-LP, 9 cases contain
616 all true-positive responders, and 2 cases are false-negative non-responders. Considering data for the 2
617 false-negative individuals more accurately, we found that patient #25 was predicted as positive for both
618 ref-LP and ML-LP with rather a high ML-score of about 0.8. An optimal LV pacing site was predicted at
619 the basal-anterior segment #7, while the referent location was in the neighboring mid-anterior segment
620 #1. The patient was initially labeled as a non-responder according to the EF10 criterion because his LV EF
621 showed an improvement of less than 10% at 2% only. However, his AHA HF functional class improved
622 from 3 to 2, and other echocardiography indices used to evaluate CRT response indicated significant LV
623 reverse remodeling in this patient, particularly a reduction both in EDV by -22% and in ESV by -25%.
624 Thus, this patient would have been surely labeled as responder if other response criteria had been used. So,
625 in this case the ML-score based positive prediction should be considered as true-positive in terms of CRT
626 response. The second patient #45 was also labeled as a non-responder as his LV EF improvement was
627 8%, which is less than 10% but close to this threshold. At the same time, this patient demonstrated also an
628 improvement in the functional class from 3 to 2, and an essential reduction in EDV by -24% while ESV
629 reduction of -3% was not as much pronounced. Based on the clinical data and simulations with ref-LP, the
630 patient was classified as true negative with an ML-score of 0.39 (< 0.5). However, the maximum ML-score
631 of 0.55 generated from the simulations at the optimal pacing site position predicts this patient as positive,
632 although the ML-score is also close to the threshold. The optimal LV pacing site was suggested to be in the
633 basal-anterolateral segment #6 which is the same as the referent position. Nevertheless, the optimal LV
634 lead position was predicted to be 34 mm away from the scar, while the suboptimal referent position was 17
635 mm closer to the scarring area. This close proximity would possibly not allow the patient to improve as
636 much as could be expected from the optimal ML-LP.

637 If we consider the 3 non-responders from the suboptimal group, each is classified as true-negative with
638 both ref-LP and ML-LP (ML-score < 0.5), and the ML-score at the optimal lead position is not much
639 different from the reference, suggesting a small chance of improvement. CRT should not possibly be
640 recommended for these patients, as it would unlikely be effective.

641 Thus, in the patient group with suboptimal reference LV lead position the ratio of patients with positive
642 to negative prediction of CRT response is 11 (79%) to 3 (21%), which is much higher than that in the entire
643 group of patients. The accuracy of the LR classifier in the group is also higher (85%). In addition, the
644 ML-score based predictions of CRT response with optimal LV lead position are supported by the difference
645 in the range of LV EF improvements in the positive and negative patients with a median of 14[11.20] for
646 responders versus 2[1.10] for non-responders within the group with suboptimal BiV pacing.

647 By contrast, in the 25% group of patients with a long distance between the reference and optimal pacing
648 sites (higher quartile of the distance distribution in our population, ranging from 79 to 117 mm) the ratio
649 of 3 responders to 11 non-responders is much lower than in the entire group. This also indicates that
650 pacing lead placement away from the optimal position is associated with a highly likely negative prognosis
651 of CRT response. Note that in a majority of non-responders from this group the pacing lead is placed
652 close to the scarring area, which could fortunately be avoided in the case of optimal lead positioning. The
653 general trend is that the closer the referent pacing site is to the scarring area, the farther away is the optimal
654 pacing site from the reference position and from the scar. Moreover, even in this far-from-optimal group, 3

655 non-responders were classified as positive at the optimal pacing site position suggesting a chance for a
656 better outcome against what empiric lead implantation provided.

657 The above results evidence a high potential of our ML-score based optimal LV lead placement for
658 stratifying CRT candidates and guiding lead implantation.

659 **4.3 Which LV lead position is better?**

660 To check the ML-score based optimization approach for other advantages, we compared ML-LP with
661 the other two opt-LPs based on model-derived feature optimization. In the first approach the personalized
662 models were computed for the LBBB activation pattern, and LAT area was derived from the simulated
663 activation map on the LV surface. The LAT sites were then used as LAT-LP to pace LV in the models.
664 This approach is similar to that automatically implemented in CRT device programming, particularly for
665 quadripolar LV electrodes. The maximal Q-LV delay used for choosing the LV active pole reflects the
666 latest activation time among the electrode tips/rings suggesting the most effective re-synchronization of the
667 ventricular activation. We implemented our personalized models to calculate the interventricular RV-LV
668 delay as a time interval between activation of the simulated LV and RV pacing sites in the LBBB pattern.
669 This feature is often used instead of Q-LV, especially in case of RV pacing.

670 Comparing the different lead optimization designs, the RV-LV delay was found to be expectedly longer
671 for LAT-LP (147 ± 42 ms) as compared to ref-LP and optimized ML-LP, TAT-LP (103 ± 40 , 96 ± 47 , 80
672 ± 37 , $p < 0.01$, respectively). Meanwhile, no pairwise difference in the average RV-LV delay was found
673 between the latter three pacing configurations. Moreover, we found no significant difference in the average
674 RV-LV delay at ref-LP between the responder and non-responder groups in our patient population (see
675 Table S6). Neither was there any correlation between the RV-LV delay and LV EF improvement ($r = -0.14$,
676 $p = 0.314$). The lack of correlation was also confirmed between the geometry distance from RV to LV pacing
677 site and EF improvement. Furthermore, no statistically significant correlation was observed between the
678 RV-LV delay and corresponding ML-score predicting the probability of EF improvement in a certain pacing
679 lead configuration ($r = 0.02$, $p = 0.904$).

680 There is no consensus on the role of RV-LV delay for optimal lead configuration. There are clinical
681 studies showing RV-LV delay to be predictive of CRT response (18). In a recent simulation study (37)
682 using personalized ventricular models, the authors showed the RV-LV delay as a significant simulated
683 feature the value of which above 60% predicts solely an acute hemodynamic response to BiV pacing. In our
684 investigation, the RV-LV delay did not demonstrate the ability to classify the patient cohort into responders
685 and non-responders with applicable accuracy (ROCAUC=0.623, $p = 0.118$). No significant difference in the
686 LV EF improvement in the groups with an RV-LV delay of more or less than 60% ($11 \pm 10\%$ versus $8 \pm 7\%$,
687 $p = 0.085$) was revealed in our cohort. The cause of the inconsistency could be an acute response to BiV
688 pacing used to train the LR classifier based on the RV-LV delay in (37). By contrast, we used clinical data
689 on long-term EF improvement in a year after the procedure where the impact of the RV-LV delay could
690 have been less important. This hypothesis is supported by our recent data from clinical observations (55).
691 We compared two groups of patients with quadripolar LV leads: one group featured an optimal choice
692 of LV pacing pole with maximal RV-LV delay while in the other group the maximal RV-LV parameter
693 could not be set for BiV pacing. We showed a faster improvement in the first group during the first 3-6
694 months after implantation. Our finding in that study coincided with the simulation data from Lee et al.
695 (37)). On the other hand, in that study we observed no difference in the LV EF improvement or ESV
696 reduction in 12 months after operation between the groups. That finding is in agreement with our model
697 predictions. In addition, our simulation data are in line with the results of a recent ENHANCE-CRT

698 study that showed no discernible difference between Q-LV delay optimized localization in comparison to
699 conventional anatomical lead location in the long-term response of non-LBBB patients (56).

700 Another tested opt-LP approach is minimum TAT based optimization of LV lead position (TAT-LP),
701 which is frequently addressed in clinical and in-silico studies. TAT is often used as a measure of ventricular
702 dyssynchrony and its reduction via BiV pacing or by other pacing settings is considered as a target for
703 stimulation design (36, 52). Many clinical trials report the effects of pacing on TAT as an estimate of its
704 quality. In clinical practice, direct assessment of both LAT and TAT is complicated and requires invasive
705 electrophysiological mapping to be performed. Currently, noninvasive body surface ECG mapping is
706 also used to solve a reverse problem of electrophysiology to assess the activation pattern in the ventricles
707 (57, 58, 59). However, it still requires manipulations on patients and can be performed for CRT patients
708 only after device implantation. By contrast, personalized cardiac models present another useful tool for
709 noninvasive prediction of LAT in LBBB and TAT for various pacing configurations prior to the procedure.

710 It is noteworthy that both simulated TAT and QRSd showed a significant reduction with each BiV pacing
711 setting as compared to an inherent LBBB activation pattern (Table 1, Fig. 4). Comparing the three optimal
712 pacing settings tested, we found essentially shorter mean values of TAT and QRSd for TAT-LP minimizing
713 TAT across the LV pacing site on the surface of the LV. At the same time, neither TAT nor QRSd showed
714 any significant pairwise intergroup difference between ML-LP, LAT-LP, and ref-LP.

715 Analyzing our clinical data, we found no correlation between LV EF improvement and either absolute
716 QRSd at BiV pacing or its change relative to the value at sinus rhythm ($-0.14 < r < 0$, $p > 0.318$). Consequently,
717 no correlation was found between simulated absolute values of TAT or QRSd at BiV pacing or their relative
718 change against the LBBB pattern (ΔTAT , $\Delta QRSd$) and ML-score ($0 < r < 0.18$, $p > 0.321$, not shown). Similar
719 results were obtained for inter- and intra-ventricular dyssynchrony indices, which highly reduced by about
720 100% at every BiV pacing setting against LBBB activation mode, but did not change to any considerable
721 degree in the optimal pacing configuration as compared to the ref-LP (Table S5).

722 Our simulation results are consistent with the simulation results published in a recent article (37). Lee
723 et al. also did not find that changes either in QRSd or in the bulk (10–90%) ventricular activation time
724 (risetime), or in the time of LV activation at BiV pacing in comparison to RV pacing were predictive of a
725 more than 10% acute hemodynamic response to BiV pacing.

726 Much more unexpectedly, our ML-LP pacing predicts higher ML-scores as compared to the other two
727 optimal pacing lead configurations LAT-LP and TAT-LP. Moreover, the average ML-scores for LAT-LP and
728 TAT-LP do not differ from that for ref-LP and between each other (Fig. 4, Table 2). A similar tendency can
729 be seen in the responders and non-responders groups. Surprisingly, in several models LAT-LP and TAT-LP
730 pacing even caused a decrease in the ML-score and in transition from the group of positive to negative
731 CRT response prediction (Fig. 5).

732 Thus, neither the longest RV-LV delay for LAT-LP nor the narrowest TAT and QRSd for TAT-LP account
733 for an essential difference in the ML-scores versus ref-LP and between each other. In contrast, ML-LP
734 provides higher ML-scores despite higher mean TAT and QRSd values compared to TAT-LP or shorter
735 RV-LV delay compared to LAT-LP. This result suggests that a uniparametric strategy (based on either TAT
736 or LAT) for targeting LV lead placement cannot guarantee the best possible effect of pacing in terms of
737 CRT response prognosis.

738 **4.4 On the regional distribution of optimal LV lead position**

739 Several clinical trials recommend avoiding apical and anterior regions for LV pacing, where possible
740 (4). Figure S2 compares the distribution of segments with LV pacing sites depending on LV optimization

741 approach. It can be seen that in ref-LP the lateral segments with LV pacing sites are more frequent (50 out
742 of the 57 cases) in our population.

743 In LAT-LP, the segment distribution is very similar to the 52 cases of LV pacing lead located in the lateral
744 wall, but inferior lateral segments are more frequent than anterior lateral ones as compared to the ref-LP
745 pacing sites. On the contrary, in TAT-LP pacing, lateral segments are less frequent (16 cases), while in the
746 majority of 21 cases (16 non-responders and 5 responders), LV pacing sites are located in anterior segments
747 against 5 cases (3 non-responders and 2 responders) for ref-LP. Thus, the prognosis of the number of
748 potentially negative patients (all of them are true non-responders in ref-LP) paced from anterior segments
749 is significantly increased at minimum TAT optimization as compared to ref-LP, suggesting worse CRT
750 response expectations in the entire population.

751 In ML-based optimization, lateral segments are more frequent (36 cases) as well as in ref-LP, but both
752 anterior (11 cases) and inferior (10 cases) segments are also representative in terms of the maximum ML-
753 score. Analyzing the 11 cases with chosen optimal anterior segments for ML-LP, we found 4 responders
754 which were predicted as true positive (ML-score > 0.5) at ML-LP, and their referent lead position was close
755 to the optimal one (in the same or neighboring segments with a small distance from the optimal to referent
756 site). The rest 7 non-responders were still predicted as negative at ML-LP (ML-score > 0.5), despite an
757 increase in their ML-score at the optimal pacing site as compared to the referent lead position. Thus, in
758 these cases even an optimal lead configuration with the highest possible ML-score is very much unlikely
759 to improve CRT response in the patients. So, our model predictions are in line with clinical observations
760 showing a small fraction of anterior segments among positive responses even for optimal lead positions.

761 **4.5 On the role of scarring area for optimal LV lead position**

762 In our study, the extent of LV myocardial damage (both absolute and relative to the surviving myocardium
763 volume) was not selected as one of the most important features by the ML feature selection algorithms
764 and thus was not included as an independent variable in our predictive LR classifier. At the same time,
765 distance from LV pacing site to scarring area (Scar-LV distance) was selected as the third most important
766 feature for CRT response prediction. It was selected by every feature selection algorithm we tested from
767 the total hybrid dataset analyzed, and was used as one of the 7 most significant input variables for building
768 the predictive LR model (see Fig. S3). This distance is the only model-driven feature that distinguishes
769 responders from non-responders in our population at the referent LV lead position (see Table 2), although,
770 no correlation was found between Scar-LV distance and LV EF improvement ($r=0.18$, $p=0.211$).

771 At the same time, we discovered a low positive correlation between ML score and Scar-LV distance at
772 the referent lead position suggesting that it has a role to play in the integrative estimate of CRT response
773 prediction ($r=0.419$, $p=0.000$). As a support for this hypothesis, we revealed strong positive correlations
774 between the change in ML-score and the change in Scar-LV distance for the optimal LV lead position
775 against the referent one ($r=0.673$ for ML-LP; 0.855 for LAT-LP; and 0.881 at TAT-LP; $p<0.01$). Here, the
776 absence of difference in average ML-score between LAT-LP, TAT-LP and ref-LP was consistent with no
777 difference in Scar-LV distance between the pacing settings. By contrast, the higher Scar-LV distances were
778 associated with the maximum ML-scores in our patients (57 ± 21 mm in ML-LP versus 32 ± 24 mm in
779 ref-LP, Table. 2).

780 Our findings are consistent with the results of clinical studies which assessed the significance of
781 postinfarction scar size for CRT response. Marsan and co-authors (60) performed MRI for CRT candidates
782 to derive LV mechanical dyssynchrony and the extent of scar tissue to predict CRT response. Higher LV
783 dyssynchronies were strongly associated with echocardiographic response to CRT, while the total extent of

784 scar correlates with non-response. Importantly, a univariable logistic regression analysis showed that the
785 presence of a match between the LV lead position and a transmural scar was also significantly associated
786 with non-response to CRT. The location of scar in the posterolateral region of the LV, which is empirically
787 thought to be a target site for LV lead implantation, was associated with lower response rates following
788 CRT (17). Pezel and co-authors (16), found no difference in the presence and extent of scar between
789 CRT responders and non-responders. However, in non-responders, the LV lead was more often over an
790 akinetic/dyskinetic area suggesting the presence of tissue lesions, a fibrotic area, or an area with myocardial
791 thickness < 6 mm. By contrast, the extent of scar core and gray zone was automatically quantified using
792 cardiac MRI analysis (15) and the highest percentage of CRT response was observed in patients with low
793 focal scar values and high QRS area before operation. Such area was calculated using vector-cardiography.
794 Lee and co-authors used LV wall thickness <5 mm as an anatomical index for scar, and this feature was not
795 shown to be predictive of an acute hemodynamic response to pacing (37). However, in every patient from
796 their cohort the LV had a wall thickness > 5 mm throughout. So, the lack of MRI information regarding
797 scarring in the cardiac tissue was mentioned as one of the limitations of the data they used. In our models
798 we accounted for such data and showed that this is essential for model predictions.

799 **4.6 On the great potential of using personalized ventricular models for CRT response** 800 **prediction**

801 In recent simulation studies, personalized cardiac models were used to reveal model-derived features
802 correlating with CRT response (61, 62, 63, 64, 65). In two recent papers, model simulations were
803 demonstrated to be predictive of the LV pacing site optimization (36, 37). In our present study, we
804 have developed an ML-based technique, using both clinical and simulated features. This technique provides
805 an LV surface map predicting areas of positive and negative response and indicating the best possible place
806 for LV lead guidance with a very high probability of CRT response.

807 Further prospective analysis of indices suggested by simulation studies could enable the clinicians to
808 test acute responses at fewer pacing sites (if any) intra-operatively and during follow up. Thus, it will
809 provide some benefits like reducing time, costs and risks to patients and enhancing the chances of a positive
810 outcome. The results of simulation studies demonstrate the potential of virtual clinical trials as a tool for
811 exploring new approaches for pacing lead placement optimization .

812 **5 LIMITATIONS**

813 There are several limitations in our study. First, the ventricular geometry in our personalized models was
814 derived from CT images obtained after CRT device implantation, not before it. Despite the supposed
815 difference in the ventricular geometry our simulated ECGs in the LBBB mode have a high correlation
816 with pre-operative clinical ECGs ($r=0.84$, $p<0.05$), thus demonstrating the effect of ventricular geometry
817 as being secondary. Second, the CRT response definition we used was based on an LV EF improvement
818 that has a low-to-moderate correlation with ventricular reverse remodeling in our patient cohort. It has
819 been recently shown in a simulation study by Rodero and co-authors (36) that cardiac reverse remodeling
820 after CRT implantation can reduce the effect of ventricular pacing. According to this hypothesis, if
821 our predictions classify a patient as positive with post-operative ventricular geometry, it is all the more
822 reasonable to expect to see this participant as positive with preoperative geometry. However, more false
823 negative predictions could be expected, and an additional prospective study with pre-operative ventricular
824 geometry will have to be performed to prove our approach.

824 Next, we have shown a high importance of the distance from the LV pacing site to the myocardial
825 damage area in ML predictions of optimal LV pacing position. In this study, we simulated LV scarring

826 area based on the labeling of damaged LV segments performed by the expert that analyzed the MRI scans.
827 A more accurate segmentation of the raw MRI data should be used to compare model predictions with a
828 different accuracy of scarring area simulation. We think more objective information on the scar and fibrosis
829 morphology may improve the predictive models of CRT response as well as optimal pacing site location.

830 In this proof-of-concept study, we used our ML-based approach to optimize BiV pacing configuration.
831 Currently, there are data emerging on the different pacing modality enhancing effects of pacing in a
832 certain patient depending on the ischemic or non-ischemic origin of CHF, LBBB or non-LBBB activation,
833 the levels of conduction system block, etc. New techniques for His-Purkinje and/or conduction system
834 pacing, selective LV, RV or BiV, or multipole pacing, epicardial versus endocardial pacing and their
835 possible combinations together with AV and VV delay optimization for the optimal ventricular fusion
836 create a challenge for the best choice. Only computational modeling provides a tool to test every possible
837 combination and suggest ones that help to optimize patient outcome. The technology we have developed is
838 capable of solving such complex problems.

839 In the present study, CRT response prediction involved simulated characteristics of ventricular activation
840 and ECG derived from electrophysiological models. However, the synchronization of ventricular contraction
841 and subsequent improvement in the mechanical performance of the ventricles is the main goal of the therapy.
842 Recent studies have shown the predictive power of the mechanical indices that could be measured from
843 CT or echocardiography images and accounted for in the predictive models of optimal pacing designs
844 (37). Moreover, electromechanical models of cardiac activity (such as reported by (65, 64, 62, 63) and
845 being developed by our team) could help perform direct simulations of LV EF, dP/dtmax changes and
846 other mechanical biomarkers of CRT response which can further improve ML based optimization of CRT
847 procedure.

848 Last but not least, in this study we had a limited data sample from 57 patients. However, to the best of
849 our knowledge, this is the largest model population used in simulation studies. Our predictive classifiers
850 based on hybrid clinical data from and computational models have demonstrated high performance with
851 accuracies higher than those achieved with classifiers developed on the basis of clinical data from a
852 thousand of patients. Still, a prospective study using our technique is needed to validate the approach and
853 confirm its usefulness for patient stratification and optimal lead guidance.

6 CONCLUSIONS

854 We have developed a new technique combining personalized heart modeling and supervised ML to predict
855 optimal LV pacing lead position in CHF candidates for CRT. We suggest an optimal LV pacing site based
856 on ML-scores from an LR classifier of positive CRT response (LV EF improvement > 10%). In a patient
857 group with suboptimal LV lead position deployed in close proximity to predicted optimal pacing site with
858 maximal ML-score, the number of positive responses is two times higher than negative responses. We
859 showed the distance from the LV pacing site to scarring area to be an important feature for predicting
860 optimal lead location.

861 This novel approach has great potential clinical implications for patient care improvement. With an
862 ML classifier on hybrid data created and thoroughly validated, the range of generated ML scores at any
863 pacing site throughout the accessible LV surface would classify this patient as a potential responder or
864 non-responder to the therapy, thus supporting individual selection for CRT. At the same time, the best
865 pacing site location predicted from model simulations and corresponding ML scores could be used for
866 guiding lead deployment during the CRT procedure and optimizing the outcome for the patient.

CONFLICT OF INTEREST STATEMENT

867 The authors declare that the research was conducted in the absence of any commercial or financial
868 relationships that could conflict of interest

AUTHOR CONTRIBUTIONS

869 OS, AD, TC, AB, and SK participated in conceptualization and design of the study, data collection,
870 processing, and analysis. SZ, TL, VL and DL performed patient selection and treatment, clinical
871 data collection and preprocessing. SZ, AB, and AD performed segmentation CT and MRI images and
872 construction of anatomical models. AD, SK, AB performed personalized computational simulations of
873 myocardial electrical activation. AD implemented algorithms of the pacing site optimization. SK, AD,
874 TC performed machine learning and built classifiers. TC contributed to the statistical analysis and data
875 interpretation. OS supervised all stages of study execution and data analysis, and was a major contributor
876 to writing the manuscript. All authors contributed to manuscript preparation and approved the final version
877 of the manuscript.

FUNDING

878 This work was supported by Russian Science Foundation grant No. 19-14-00134.

REFERENCES

- 879 1 .Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC
880 Guidelines on cardiac pacing and cardiac resynchronization therapy **42** (2021) 3427–3520. doi:10.
881 1093/eurheartj/ehab364.
- 882 2 .Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding non-responders to cardiac
883 resynchronization therapy: A practical guide **38** (2017) 1463–1472. doi:10.1093/eurheartj/ehw270.
- 884 3 .Wouters PC, Vernooij K, Cramer MJ, Prinzen FW, Meine M. Optimizing lead placement for pacing in
885 dyssynchronous heart failure: The patient in the lead. *Heart Rhythm* **18** (2021) 1024–1032. doi:10.
886 1016/j.hrthm.2021.02.011.
- 887 4 .Butter C, Georgi C, Stockburger M. Optimal CRT Implantation—Where and How To Place the
888 Left-Ventricular Lead? **18** (2021) 329–344. doi:10.1007/s11897-021-00528-9.
- 889 5 .Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, et al. Optimized implementation
890 of cardiac resynchronization therapy: a call for action for referral and optimization of care: A joint
891 position statement from the Heart Failure Association (HFA), European Heart Rhythm Association
892 (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of
893 Cardiology. *European Journal of Heart Failure* **22** (2020) 2349–2369. doi:10.1002/ejhf.2046.
- 894 6 .Sieniewicz BJ, Gould J, Porter B, Sidhu BS, Behar JM, Claridge S, et al. Optimal site selection and
895 image fusion guidance technology to facilitate cardiac resynchronization therapy. *Expert Review of*
896 *Medical Devices* **15** (2018) 555–570. doi:10.1080/17434440.2018.1502084.
- 897 7 .Varma N, Baker J, Tomassoni G, Love CJ, Martin D, Sheppard R, et al. Left Ventricular Enlargement,
898 Cardiac Resynchronization Therapy Efficacy, and Impact of MultiPoint Pacing. *Circulation. Arrhythmia*
899 *and electrophysiology* **13** (2020) e008680. doi:10.1161/CIRCEP.120.008680.
- 900 8 .Engels EB, Vis A, van Rees BD, Marcantoni L, Zanon F, Vernooij K, et al. Improved acute
901 haemodynamic response to cardiac resynchronization therapy using multipoint pacing cannot solely
902 be explained by better resynchronization. *Journal of Electrocardiology* **51** (2018) S61–S66.
903 doi:10.1016/j.jelectrocard.2018.07.011.

- 904 **9** .Massacesi C, Ceriello L, Maturo F, Porreca A, Appignani M, Di Girolamo E. Cardiac resynchronization
905 therapy with multipoint pacing via quadripolar lead versus traditional biventricular pacing: A systematic
906 review and meta-analysis of clinical studies on hemodynamic, clinical, and prognostic parameters.
907 *Heart Rhythm O2* **2** (2021) 682–690. doi:10.1016/j.hroo.2021.09.012.
- 908 **10** .Yamanturk YY, Candemir B, Baskovski E, Esenboga K. Overview of Current Strategies Aiming at
909 Improving Response to Cardiac Resynchronization Therapy. *The Anatolian Journal of Cardiology* **26**
910 (2022) 346–353. doi:10.5152/AnatolJCardiol.2022.1647.
- 911 **11** .Sharma PS, Vijayaraman P. Conduction system pacing for cardiac resynchronisation. *Arrhythmia and*
912 *Electrophysiology Review* **10** (2021) 51–58. doi:10.15420/AER.2020.45.
- 913 **12** .Varma N, O'Donnell D, Bassiouny M, Ritter P, Pappone C, Mangual J, et al. Programming cardiac
914 resynchronization therapy for electrical synchrony: Reaching beyond left bundle branch block and left
915 ventricular activation delay. *Journal of the American Heart Association* **7** (2018) 1–12. doi:10.1161/
916 JAHA.117.007489.
- 917 **13** .Strik M, Ploux S, Jankelson L, Bordachar P. Non-invasive cardiac mapping for non-response in cardiac
918 resynchronization therapy. *Annals of Medicine* **51** (2019) 109–117. doi:10.1080/07853890.2019.
919 1616109.
- 920 **14** .Ploux S, Lumens J, Whinnett Z, Montaudon M, Strom M, Ramanathan C, et al. Noninvasive
921 electrocardiographic mapping to improve patient selection for cardiac resynchronization therapy:
922 Beyond QRS duration and left bundle branch block morphology. *Journal of the American College of*
923 *Cardiology* **61** (2013) 2435–2443. doi:10.1016/j.jacc.2013.01.093.
- 924 **15** .Nguyễn UC, Claridge S, Vernooy K, Engels EB, Razavi R, Rinaldi CA, et al. Relationship between
925 vectorcardiographic QRSarea, myocardial scar quantification, and response to cardiac resynchronization
926 therapy. *Journal of Electrocardiology* **51** (2018) 457–463. doi:10.1016/J.JELECTROCARD.2018.01.
927 009.
- 928 **16** .Pezel T, Mika D, Logeart D, Cohen-Solal A, Beauvais F, Henry P, et al. Characterization of non-
929 response to cardiac resynchronization therapy by post-procedural computed tomography. *PACE -*
930 *Pacing and Clinical Electrophysiology* **44** (2021) 135–144. doi:10.1111/pace.14134.
- 931 **17** .Chalil S, Foley PW, Muyhaldeen SA, Patel KC, Yousef ZR, Smith RE, et al. Late gadolinium
932 enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization
933 therapy in patients with ischaemic cardiomyopathy. *Europace* **9** (2007) 1031–1037. doi:10.1093/
934 europace/eum133.
- 935 **18** .Gold MR, Yu Y, Wold N, Day JD. The role of interventricular conduction delay to predict clinical
936 response with cardiac resynchronization therapy. *Heart Rhythm* **14** (2017) 1748–1755. doi:10.1016/j.
937 hrthm.2017.10.016.
- 938 **19** .Becker M, Franke A, Breithardt OA, Ocklenburg C, Kaminski T, Kramann R, et al. Impact of left
939 ventricular lead position on the efficacy of cardiac resynchronisation therapy: A two-dimensional strain
940 echocardiography study. *Heart* **93** (2007) 1197–1203. doi:10.1136/hrt.2006.095612.
- 941 **20** .Allen LaPointe NM, Ali-Ahmed F, Dalgaard F, Kosinski AS, Schmidler GS, Al-Khatib SM. Outcomes
942 of Cardiac Resynchronization Therapy with Image-Guided Left Ventricular Lead Placement at the Site
943 of Latest Mechanical Activation: A Systematic Review and Meta-Analysis. *Journal of Interventional*
944 *Cardiology* **2022** (2022) 1–10. doi:10.1155/2022/6285894.
- 945 **21** .Zweerink A, Salden OA, van Everdingen WM, de Roest GJ, van de Ven PM, Cramer MJ, et al.
946 Hemodynamic Optimization in Cardiac Resynchronization Therapy: Should We Aim for dP/dtmax or
947 Stroke Work? *JACC: Clinical Electrophysiology* **5** (2019) 1013–1025. doi:10.1016/j.jacep.2019.05.020.

- 948 **22** .Bank AJ, Brown CD, Burns KV, Espinosa EA, Harbin MM. Electrical dyssynchrony mapping and
949 cardiac resynchronization therapy. *Journal of Electrocardiology* **74** (2022) 73–81. doi:10.1016/j.
950 jelectrocard.2022.08.006.
- 951 **23** .Zoppo F, Cocciolo A, Mangiameli D, Perazza L, Corrado A. ECG optimisation for CRT systems in the
952 era of automatic algorithms: a comprehensive review. *International Journal of Arrhythmia* **23** (2022).
953 doi:10.1186/s42444-022-00067-x.
- 954 **24** .Van Everdingen WM, Zweerink A, Cramer MJ, Doevendans PA, Nguyễn UC, Van Rossum AC, et al.
955 Can we use the intrinsic left ventricular delay (QLV) to optimize the pacing configuration for cardiac
956 resynchronization therapy with a quadripolar left ventricular lead? *Circulation: Arrhythmia and*
957 *Electrophysiology* **11** (2018) 1–12. doi:10.1161/CIRCEP.117.005912.
- 958 **25** .Tamborero D, Vidal B, Tolosana JM, Sitges M, Berruezo A, Silva E, et al. Electrocardiographic
959 versus echocardiographic optimization of the interventricular pacing delay in patients undergoing
960 cardiac resynchronization therapy. *Journal of Cardiovascular Electrophysiology* **22** (2011) 1129–1134.
961 doi:10.1111/j.1540-8167.2011.02085.x.
- 962 **26** .Field ME, Yu N, Wold N, Gold MR. Comparison of measures of ventricular delay on cardiac
963 resynchronization therapy response. *Heart Rhythm* **17** (2020) 615–620. doi:10.1016/j.hrthm.2019.11.
964 023.
- 965 **27** .Cikes M, Sanchez-Martinez S, Claggett B, Duchateau N, Piella G, Butakoff C, et al. Machine learning-
966 based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy.
967 *European Journal of Heart Failure* **21** (2019) 74–85. doi:https://doi.org/10.1002/ejhf.1333.
- 968 **28** .Feeny AK, Rickard J, Patel D, Toro S, Trulock KM, Park CJ, et al. Machine learning prediction of
969 response to cardiac resynchronization therapy. *Circulation: Arrhythmia and Electrophysiology* **12**
970 (2019) e007316. doi:10.1161/CIRCEP.119.007316.
- 971 **29** .Kalscheur MM, Kipp RT, Tattersall MC, Mei C, Buhr KA, Demets DL, et al. Machine Learning
972 Algorithm Predicts Cardiac Resynchronization Therapy Outcomes: Lessons from the COMPANION
973 Trial. *Circulation: Arrhythmia and Electrophysiology* **11** (2018). doi:10.1161/CIRCEP.117.005499.
- 974 **30** .Tokodi M, Schwertner WR, Kovács A, Tóser Z, Staub L, Sárkány A, et al. Machine learning-based
975 mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT
976 score. *European Heart Journal* **41** (2020) 1747–1756. doi:10.1093/eurheartj/ehz902.
- 977 **31** .Tokodi M, Behon A, Merkel ED, Kovács A, Tóser Z, Sárkány A, et al. Sex-specific patterns of mortality
978 predictors among patients undergoing cardiac resynchronization therapy: A machine learning approach.
979 *Frontiers in Cardiovascular Medicine* **8** (2021) 87. doi:10.3389/fcvm.2021.611055.
- 980 **32** .Hu SY, Santus E, Forsyth AW, Malhotra D, Haimson J, Chatterjee NA, et al. Can machine learning
981 improve patient selection for cardiac resynchronization therapy? *PLOS ONE* **14** (2019) 1–13. doi:10.
982 1371/journal.pone.0222397.
- 983 **33** .Feeny AK, Rickard J, Trulock KM, Patel D, Toro S, Moennich LA, et al. Machine learning of 12-
984 lead qrs waveforms to identify cardiac resynchronization therapy patients with differential outcomes.
985 *Circulation: Arrhythmia and Electrophysiology* **13** (2020) e008210. doi:10.1161/CIRCEP.119.008210.
- 986 **34** .Lee A, Nguyen U, Razeghi O, Gould J, Sidhu B, Sieniewicz B, et al. A rule-based method for predicting
987 the electrical activation of the heart with cardiac resynchronization therapy from non-invasive clinical
988 data. *Medical Image Analysis* **57** (2019) 197–213. doi:https://doi.org/10.1016/j.media.2019.06.017.
- 989 **35** .Villongco CT, Krummen DE, Omens JH, McCulloch AD. Non-invasive, model-based measures of
990 ventricular electrical dyssynchrony for predicting CRT outcomes. *EP Europace* **18** (2016) iv104–iv112.
991 doi:10.1093/europace/euw356.

- 992 **36**. Rodero C, Strocchi M, Lee AW, Rinaldi CA, Vigmond EJ, Plank G, et al. Impact of anatomical reverse
993 remodelling in the design of optimal quadripolar pacing leads: A computational study. *Computers in*
994 *Biology and Medicine* **140** (2022) 105073. doi:10.1016/j.combiomed.2021.105073.
- 995 **37**. Lee AW, Razeghi O, Solis-Lemus JA, Strocchi M, Sidhu B, Gould J, et al. Non-invasive simulated
996 electrical and measured mechanical indices predict response to cardiac resynchronization therapy.
997 *Computers in Biology and Medicine* **138** (2021) 104872. doi:10.1016/j.combiomed.2021.104872.
- 998 **38**. Khamzin S, Dokuchaev A, Bazhutina A, Chumarnaya T, Zubarev S, Lyubimtseva T, et al. Machine
999 Learning Prediction of Cardiac Resynchronisation Therapy Response From Combination of Clinical
1000 and Model-Driven Data. *Frontiers in Physiology* **12** (2021). doi:10.3389/fphys.2021.753282.
- 1001 **39**. Bayer JD, Blake RC, Plank G, Trayanova NA. A novel rule-based algorithm for assigning myocardial
1002 fiber orientation to computational heart models. *Annals of Biomedical Engineering* **40** (2012) 2243–
1003 2254. doi:10.1007/s10439-012-0593-5.
- 1004 **40**. Keener JP. An eikonal-curvature equation for action potential propagation in myocardium. *Journal of*
1005 *Mathematical Biology* **29** (1991) 629–651. doi:10.1007/BF00163916.
- 1006 **41**. Franzone PC, Guerri L. Spreading of excitation in 3-d models of the anisotropic cardiac tissue.
1007 i. validation of the eikonal model. *Mathematical Biosciences* **113** (1993) 145–209. doi:10.1016/
1008 0025-5564(93)90001-Q.
- 1009 **42**. Pezzuto S, Kal’avský P, Potse M, Prinzen FW, Auricchio A, Krause R. Evaluation of a rapid anisotropic
1010 model for ecg simulation. *Frontiers in Physiology* **0** (2017) 265. doi:10.3389/FPHYS.2017.00265.
- 1011 **43**. Pullan AJ, Tomlinson KA, Hunter PJ. A finite element method for an eikonal equation model of
1012 myocardial excitation wavefront propagation. <http://dx.doi.org/10.1137/S0036139901389513> **63** (2006)
1013 324–350. doi:10.1137/S0036139901389513.
- 1014 **44**. Camps J, Lawson B, Drovandi C, Mincholé A, Wang ZJ, Grau V, et al. Inference of ventricular
1015 activation properties from non-invasive electrocardiography. *Medical Image Analysis* **73** (2021)
1016 102143. doi:10.1016/j.media.2021.102143.
- 1017 **45**. Pezzuto S, Prinzen FW, Potse M, Maffessanti F, Regoli F, Caputo ML, et al. Reconstruction of
1018 three-dimensional biventricular activation based on the 12-lead electrocardiogram via patient-specific
1019 modelling. *Europace* **23** (2021) 640–647. doi:10.1093/europace/eaab330.
- 1020 **46**. Geselowitz D. On the theory of the electrocardiogram. *Proceedings of the IEEE* **77** (1989) 857–876.
1021 doi:10.1109/5.29327.
- 1022 **47**. Plesinger F, van Stipdonk AM, Smisek R, Halamek J, Jurak P, Maass AH, et al. Fully automated
1023 QRS area measurement for predicting response to cardiac resynchronization therapy. *Journal of*
1024 *Electrocardiology* **63** (2020) 159–163. doi:10.1016/j.jelectrocard.2019.07.003.
- 1025 **48**. Sahli Costabal F, Hurtado DE, Kuhl E. Generating Purkinje networks in the human heart. *Journal of*
1026 *Biomechanics* **49** (2016) 2455–2465. doi:10.1016/j.jbiomech.2015.12.025.
- 1027 **49**. Williams CK, Rasmussen CE. *Gaussian processes for machine learning*, vol. 2 (MIT press Cambridge,
1028 MA) (2006).
- 1029 **50**. Sommer A, Kronborg MB, Nørgaard BL, Poulsen SH, Bouchelouche K, Böttcher M, et al.
1030 Multimodality imaging-guided left ventricular lead placement in cardiac resynchronization therapy: a
1031 randomized controlled trial. *European Journal of Heart Failure* **18** (2016) 1365–1374. doi:10.1002/
1032 ejhf.530.
- 1033 **51**. Yagishita D, Shoda M, Yagishita Y, Ejima K, Hagiwara N. Time interval from left ventricular stimulation
1034 to QRS onset is a novel predictor of nonresponse to cardiac resynchronization therapy. *Heart Rhythm*
1035 **16** (2019) 395–402. doi:10.1016/j.hrthm.2018.08.035.

- 1036 **52** .Pereira H, Jackson TA, Claridge S, Behar JM, Yao C, Sieniewicz B, et al. Comparison of
1037 Echocardiographic and Electrocardiographic Mapping for Cardiac Resynchronisation Therapy
1038 Optimisation. *Cardiology Research and Practice* **2019** (2019). doi:10.1155/2019/4351693.
- 1039 **53** .Logg A, Wells GN. Dofin: Automated finite element computing. *ACM Trans. Math. Softw.* **37** (2010).
1040 doi:10.1145/1731022.1731030.
- 1041 **54** .Bingham E, Chen JP, Jankowiak M, Obermeyer F, Pradhan N, Karaletsos T, et al. Pyro: Deep Universal
1042 Probabilistic Programming. *Journal of Machine Learning Research* (2018).
- 1043 **55** .Chumarnaya TV, Lyubimtseva TA, Lebedeva VK, Gasimova NZ, Lebedev DS, Solovieva OE.
1044 Evaluation of interventricular delay during cardiac resynchronization therapy in patients with
1045 quadripolar systems in long-term postoperative follow-up. *Russian Journal of Cardiology* **27** (2022)
1046 60–69. doi:10.15829/1560-4071-2022-5121.
- 1047 **56** .Singh JP, Berger RD, Doshi RN, Lloyd M, Moore D, Stone J, et al. Targeted Left Ventricular Lead
1048 Implantation Strategy for Non-Left Bundle Branch Block Patients: The ENHANCE CRT Study. *JACC:
1049 Clinical Electrophysiology* **6** (2020) 1171–1181. doi:10.1016/j.jacep.2020.04.034.
- 1050 **57** .Sieniewicz BJ, Jackson T, Claridge S, Pereira H, Gould J, Sidhu B, et al. Optimization of CRT
1051 programming using non-invasive electrocardiographic imaging to assess the acute electrical effects of
1052 multipoint pacing. *Journal of Arrhythmia* **35** (2019) 267–275. doi:10.1002/joa3.12153.
- 1053 **58** .Zweerink A, Zubarev S, Bakelants E, Potyagaylo D, Stettler C, Chmelevsky M, et al. His-Optimized
1054 Cardiac Resynchronization Therapy With Ventricular Fusion Pacing for Electrical Resynchronization in
1055 Heart Failure. *JACC: Clinical Electrophysiology* **7** (2021) 881–892. doi:10.1016/j.jacep.2020.11.029.
- 1056 **59** .Sedova K, Repin K, Donin G, Van Dam P, Kautzner J. Clinical utility of body surface potential mapping
1057 in CRT patients. *Arrhythmia and Electrophysiology Review* **10** (2021) 113–119. doi:10.15420/aer.2021.
1058 14.
- 1059 **60** .Marsan NA, Westenberg JJ, Ypenburg C, van Bommel RJ, Roes S, Delgado V, et al. Magnetic
1060 resonance imaging and response to cardiac resynchronization therapy: relative merits of left ventricular
1061 dyssynchrony and scar tissue. *European Heart Journal* **30** (2009) 2360–2367. doi:10.1093/
1062 EURHEARTJ/EHP280.
- 1063 **61** .Villongco CT, Krummen DE, Omens JH, McCulloch AD. Non-invasive, model-based measures of
1064 ventricular electrical dyssynchrony for predicting CRT outcomes. *Europace : European pacing,
1065 arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing,
1066 arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* **18** (2016)
1067 iv104–iv112. doi:10.1093/europace/euw356.
- 1068 **62** .Lee AWC, Mendonca Costa C, Strocchi M, Rinaldi CA, Niederer SA. Computational Modeling for
1069 Cardiac Resynchronization Therapy. *Journal of Cardiovascular Translational Research* **11** (2018)
1070 92–108. doi:10.1007/s12265-017-9779-4.
- 1071 **63** .Sermesant M, Chabiniok R, Chinchapatnam P, Mansi T, Billet F, Moireau P, et al. Patient-specific
1072 electromechanical models of the heart for the prediction of pacing acute effects in CRT: A preliminary
1073 clinical validation. *Medical Image Analysis* **16** (2012) 201–215. doi:10.1016/j.media.2011.07.003.
- 1074 **64** .Okada Ji, Washio T, Nakagawa M, Watanabe M, Kadooka Y, Kariya T, et al. Multi-scale, tailor-made
1075 heart simulation can predict the effect of cardiac resynchronization therapy. *Journal of Molecular and
1076 Cellular Cardiology* **108** (2017) 17–23. doi:10.1016/j.yjmcc.2017.05.006.
- 1077 **65** .Isotani A, Yoneda K, Iwamura T, Watanabe M, ichi Okada J, Washio T, et al. Patient-specific heart
1078 simulation can identify non-responders to cardiac resynchronization therapy. *Heart and Vessels* **35**
1079 (2020) 1135–1147. doi:10.1007/s00380-020-01577-1.

FIGURE CAPTIONS




Figure 1. Schematic outline of the ML model development. I. Building and calculation of a personalized electrophysiological ventricular model: 1. Processing of the CT imaging data. 2. Segmentation of the finite element meshes of the torso, lungs and ventricles; 2*. Personalization of the ventricular model: A. Rule-based generation of myocardial fibers. B. Assignment of the scar/fibrosis area in the ventricles (shown in back) and computing of the ventricular activation map at the baseline LBBB pattern and BiV pacing with clinical lead position. 3. Calculation of ECG signals from the ventricular activation map. II. Development of a supervised machine learning classifier: creation of a dataset contacting combination of the clinical data and simulated features from the electrophysiological model from each of the 57 patients labeled into responders and non-responders, supervised training of a ML classifier and calculation of ML-scores of CRT response.




Figure 2. Schematic outline of an algorithm for finding the optimal LV pacing site position on the epicardial LV surface of a personalized ventricular model. The pipeline includes three major steps: 1. Precalculation of the ventricular activation maps from the personalized model at BiV pacing from the centers of available segments of the AHA LV model with the exception of the septal and postinfarction scar segments (marked as dark gray at the AHA LV scheme on the left panel). 2. Iterative Bayesian Optimization procedure to interpolate ML-scores on the LV surface, which includes: computation of simulated features which in combination with patient clinical data are fed to the LR classifier for creation of an initial array of the ML-scores for interpolation on the LV surface. Gaussian Process (GP) regression model trained on the current ML-score array for estimating a GP acquisition function $L(\mu, \sigma)$ and predicting ML-score values on the entire available LV surface (see two color maps on the LV surface with shades of red for ML-score > 0.5 and shades of blue for ML-score < 0.5); finding a target point candidate, in which the maximum ML-score of the acquisition function is approached; calculation of a new ventricular activation map and simulated features at BiV pacing with the LV site located at the current candidate point. The simulated features in the next iteration step are fed again to the LR classifier to generate the ML-score which is then added to the ML-score array for retraining the GP regression for further interpolation of ML-score on the LV surface. 3. If two iterations of the algorithm predict the same candidate point, the algorithm is considered to converge and the last point with maximal ML-score value provides an optimal LV pacing site. Resulting ML-score map is shown on the LV surface of the personalized LV model and on the LV AHA segment scheme.




Figure 3. Examples of optimal LV pacing sites in personalized ventricular models. Two color maps of the ML-value are shown on the LV surface of personalized models and on the LV AHA segment schemes. Dark gray at the AHA LV scheme marks segments containing postinfarction scar, which are excluded from pacing. Shades of red show ML-scores > 0.5 and shades of blue show ML-scores < 0.5. Blue and red dots show locations of the clinical and optimal LV pacing sites. From left to right are shown examples of the ML-score map in the clinical responder (patient #2), non-responder (patient #1), and non-responder (true negative at the ref-LP) predicted as positive to CRT response at the optimal ML-based lead position (patient #7).




Figure 4. Dependence of CRT response characteristics on the LV pacing lead position. Top panel: ML-score at baseline LBBB activation and at different LV pacing lead positions. Bottom panel: TAT at LBBB and different LV pacing sites. Comparison of dependent groups was performed using the Friedman's test, followed by a pairwise comparison adjusted for multiple comparison.

TABLE CAPTIONS




Figure 5. Transitions from negative to positive prediction of CRT response and reverse transitions when switching from ref-LP to opt-LP . Top: ML-LP; Middle: LAT-LP; Bottom: TAT-LP.

Table 1. Statistics of simulated total activation time 95% (TAT95) and QRSd at baseline LBBB activation and BiV pacing with different LV lead positions in the total patient cohort and groups of responders and non-responders.

Simulated feature	Total Cohort (n=57)			Responders (n=23)			Non-responders (n=34)			
	Value	Increment (BiV-LBBB)	Increment (opt-LP – ref-LP)	Value	Increment (BiV-LBBB)	Increment (opt-LP – ref-LP)	Value	Increment (BiV-LBBB)	Increment (opt-LP – ref-LP)	
TAT95, ms	LBBB	150±26		151±21			149±29			
	ref-LP	100±20*	-50±26	98±14*	-53±20		102±23*	-47±29		
	ML-LP	104±26*	-46±30	4±13	101±15*	-50±19	3±6	106±32*	-43±36	4±16
	LAT-LP	100±21	-50±28	0±8	98±15*	-53±21	0±6	102±24*	-47±31	0±9
	TAT-LP	91±18*\$\$&	-59±27\$&	-10±7&	89±13*\$\$&	-62±20\$&	-9±6&	92±21*\$\$&	-57±31\$&	-10±7&
QRSd, ms	LBBB	189±24		191±20			188±27			
	ref-LP	144±20*	-45±25		142±15*	-49±20		145±23*	-42±28	
	ML-LP	146±27*	-43±29	2±14	143±15*	-47±20	2±6	148±33*	-40±34	2±17
	LAT-LP	143±21*	-46±26	-1±9	141±15*	-50±20	-1±7	145±25*	-43±30	-1±10
	TAT-LP	134±19*\$\$&	-55±25\$&	-10±7&	133±14*\$\$&	-58±20\$&	-9±7&	134±22*\$\$&	-53±28\$&	-11±8&

Mean±SD

* - p<0.05, * - p<0.01 opt-LP vs LBBB. \$ - p<0.05, \$ - p<0.01 opt-LP vs ref-LP. & - p<0.05, & - p<0.01 opt-LP vs ML-LP. Comparison of dependent groups was performed using Friedman's test, followed by a pairwise comparison adjusted for multiple comparisons.

- p<0.05, # - p<0.01 Responders vs Non-responders. Comparison between two independent groups was carried out using Mann-Whitney test.

Table 2. Statistics of the ML-score and distance from LV pacing site to the scar area (Scar-LV distance) at different pacing Lv lead positions in the total patient cohort and groups of responders and non-responders

Simulated feature		Total Cohort (n=57)		Responders (n=23)		Non-responders (n=34)	
		Value	Increment (opt-LP – ref-LP)	Value	Increment (opt-LP – ref-LP)	Value	Increment (opt-LP – ref-LP)
ML-score	ref-LP	0.41±0.31		0.64±0.3		0.25±0.22 ^{##}	
	ML-LP	0.58±0.3 ^{\$}	0.17±0.14	0.78±0.22 ^{\$}	0.14±0.13	0.45±0.27 ^{\$\$\$}	0.19±0.14
	LAT-LP	0.38±0.33 ^{&}	-0.02±0.13 ^{&}	0.59±0.34 ^{&}	-0.05±0.12 ^{&}	0.24±0.24 ^{&##}	-0.01±0.14 ^{&}
	TAT-LP	0.37±0.3 ^{&}	-0.04±0.16 ^{&}	0.54±0.3 ^{&}	-0.10±0.16 ^{&}	0.26±0.25 ^{&##}	0.01±0.15 ^{&#}
Scar-LV distance, mm	refLP	32±24		39±22		26±24 [#]	
	ML-LP	57±21 ^{\$}	26±20	59±20 ^{\$}	20±17	56±21 ^{\$}	30±22
	LAT-LP	24±27 ^{&}	-8±24 ^{&}	27±27 ^{&}	-12±18 ^{&}	22±27 ^{&}	-4±27 ^{&}
	TAT-LP	19±19 ^{&}	-13±27 ^{&}	16±18 ^{*&}	-23±27 ^{&}	20±20 ^{&}	-6±26 ^{&#}

Mean±SD

* - p<0.05, * - p<0.01 opt-LP vs LBBB. \$ - p<0.05, \$ - p<0.01 opt-LP vs ref-LP. & - p<0.05, & - p<0.01 opt-LP vs ML-LP. Comparison of dependent groups was performed using Friedman's test, followed by a pairwise comparison adjusted for multiple comparisons.

- p<0.05, # - p<0.01 Responders vs Non-responders. Comparison between two independent groups was carried out using Mann-Whitney test.